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ABSTRACT
THE THERMODYNAMIC DISSECTION AND DESIGN OF HIGH-AFFINITY
ANTIBODIES
Sriram Jakkaraju, Ph.D.
Department of Chemistry and Biochemistry
Northern Illinois University, 2015
James R. Horn, Director
Antibody fragments are attractive alternatives to conventional antibodies for both
therapeutic and diagnostic applications. One example, single-domain VHH antibodies, which are
derived from camelid heavy-chain-only antibodies, display comparable binding affinity to
conventional antibodies despite the significantly reduced binding interface. Here, an anti-RNase
A VHH single-domain antibody and its antigen, RNase A, are used as a model antibody-antigen
system for the three studies described in this dissertation.
Despite the fact that affinity maturation of an antibody for its target is quite common
using techniques such as phage & yeast display, very little is known about the thermodynamic
origins of enhanced affinity for in vitro matured antibodies. Here, in the first study, we examined
an in vitro affinity-matured anti-RNase A VHH, VHH-Mat, by dissecting the residue specific
contributions towards the antibody’s 100-fold enhanced binding affinity. ΔΔΔG° values
calculated from alanine-scanning mutagenesis indicated that only four of the nine residues were
critical in VHH-Mat’s increased affinity. The thermodynamic origins of enhance affinity were
examined through an analysis of the binding energetics of a series of site-directed mutants. These
variants allowed the examination of individual and grouped residue contributions towards
enhanced affinity. Thermodynamic analysis suggested enhanced affinity was due to a

combination of both additive and non-additive (i.e., cooperative) interactions between interface
residues, with the later playing a more significant role.
As an alternative to interface affinity maturation, the observed antibody binding affinity
may be enhanced through an increase in binding valency (i.e, multi-valent interactions). Here,
using the protein rhizavidin, a general biotin/avidin-based reagent was developed that can be
used to generate bivalent antibody complexes with enhanced observed binding affinity. A
bivalent VHH antibody was obtained though in vitro biotinylation of a C-terminal Avitag,
followed by the formation of a bivalent (VHH)2-rhizavidin complex. The intact 2:1 (VHH)2rhizavidin complex stoichiometry was confirmed by size exclusion chromatography and SDSPAGE. Surface plasmon resonance was used to evaluate the observed binding constant and
association/dissociation kinetics, which suggested at least a 100-fold increase in the apparent
affinity for the bivalent sdAb complex, relative to the original monovalent VHH antibody.
Furthermore, the enhanced interaction was driven by (VHH)2-rhizavidin’s slower off-rate.
To enhance the use of the VHH domain for synthetic libraries, we investigated potential
sequence diversity of CDR4, a non-hypervariable, interface loop that is structurally well-placed
to make potential contacts with antigens. The anti-RNase A VHH/RNase A system was used as a
model system, as only CDR1 and CDR3 are directly involved in antigen recognition.
Consequently, RNase A can be used as bait to select for functional (i.e., folded) CDR4 VHH
variants. Degenerate codons were used to insert all 20 amino acids, with loop lengths ranging
from four to seven, into the CDR4 loop. Results suggested loop lengths of five residues showed
were favored. Additional selection of the five-residue CDR4 library followed by DNA
sequencing was performed to evaluate amino acid and loop length diversity that will help shape
our next generation synthetic VHH libraries.
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CHAPTER 1
INTRODUCTION

Antibody fragments play a significant role in life science applications, such as
diagnostics and therapeutics. Traditionally, antibodies are obtained through animal immunization,
but today recombinant antibody libraries (e.g., phage, yeast display) have become an exciting
alternative to generate antibodies or obtain affinity-maturated antibodies. In the first project
(Chapter 2), we examined the thermodynamic origins of enhanced affinity by investigating the
role of residue-specific contributions. In the second project (Chapter 3), a rhizavidin biotin
system was used to create a bivalent sdAb, which improved its functional avidity, compared to
monovalent sdAb. In the third project (Chapter 4), synthetic libraries were used to explore amino
acid and loop length diversity in nonhypervariable CDR4, which will be used to guide our next
generation libraries.

Antibodies
Antibodies or immunoglobulins (Ig) play an important role in the immune response and
are invaluable affinity reagents for numerous life science applications. German scientist Emil
von Behring was given credit for discovering antibodies in 1901 (1). Antibodies are produced by
B-cell lymphocytes and their main role includes targeting foreign antigens such as viruses,
bacteria, fungus and all other small parasites. Their ability to bind foreign antigens with high
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affinity also makes them invaluable affinity reagents for numerous life science applications. For
example, antibodies are increasingly used for protein therapeutic applications (2).
Immunoglobulin G (IgG) is the most abundant antibody type in the human body where it
is found in blood, lymph fluid, cerebrospinal fluid, and peritoneal fluid (3). IgG are subdivided
into four subclasses based on the number of disulfide bonds in the hinge region. These antibodies
have a Y-shaped structure (Figure 1.1), consisting of two heavy and two light chain polypeptides
with a total molecular weight of approximately 150 kDa. Both heavy and light chains are highly
conserved in humans (4). The two heavy chains are covalently linked to each other by disulfide
bonds and each heavy chain is linked to light chain with disulfide bonds. As shown in Figure 1.1,
each heavy chain consists of three constant domains (CH1, CH2 and CH3) and a variable domain
(VH), while the light chains consist of one constant domain (CL) and variable domain (VL). At
the tips of the Y-shaped motif are two antigen binding regions consisting of three hypervariable
loops from each variable domain (VH and VL) which are called complementarity determining
regions (CDRs).
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Figure 1.1: Cartoon is representation of a conventional IgG
antibody. IgG antibodies are comprised of two heavy chain
peptides, each with one variable (VH) and three constant domains
(CH1-3), and two light chains, each with one variable (VL)
domain, and one constant (CL) domain.

Although conventional antibodies are widely-used reagents in basic research and
diagnostics, their large size is not always favorable for some diagnostic and therapeutic
applications (5). Consequently, protein engineering and recombinant DNA strategies have
produced antibody fragments with reduced size, such as single chain antibody fragments (scFv)
and single-domain antibodies (VHH, VH and NAR V), These antibody variants are widely
studied in research are show increased use in pharmaceutical applications (6-8) due to their
stability, expression and ease of manipulation using standard molecular biology techniques.

4

Single-Domain Antibodies
The Camelidae family (e.g. llamas, camels) possess a unique class of heavy-chain only
antibodies that were first discovered by Hammers-Casterman et al (9). These heavy-chain-only
antibodies (HCAbs) are devoid of light chains and the first heavy chain constant domain (10).
While heavy-chain only antibodies have been observed in the sera of humans as nonfunctional
resulting in a pathological disorder (11, 12), these unique Cadmidae antibodies maintain function
and interact with the antigen by virtue of single-domain, referred to as VHH. Reducing the size
of the interface and molecular scaffold reduces the chemical complexity in antibody-antigen
interface (13). Compared to six CDRs in conventional IgG antibodies, three from each VH and
VL domain, single-domain antibodies possess only three CDRs. The heavy-chain-only VHH
domain can be expressed independently, making it the smallest antibody-binding unit. It is often
referred to as a single-domain antibody or commercially as a Nanobody (14, 15). There is high
sequence diversity between VHH and human VH family III, the most frequently observed VH
family (16, 17).
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Figure 1.2: Cartoon representation of heavy-chain only antibody
and single-domain VHH. (A) Camelid heavy chain only antibody
consisting two constant domains (CH2-3) and one variable domain
VHH. (B) A single antibody VHH domain consists of three
hypervariable loops (CDR1-3) colored in red.

The VHH structure can be divided into two main regions based on sequence variability,
the hypervariable region (HV) and the conserved framework region (FR) (4). As shown in figure
1.4, the VHH domain consists of nine β-strands (A-B-C-C’-C”-D-E-F-G), which make up a βsheet sandwich. Hypervariable regions CDRs are located in the loops connect β strands B-C
(CDR1), C’-C” (CDR2), and the F-G (CDR3). Sequence alignment of the VHH and VH domains
show significant sequence similarities within the FR regions, with a few noteworthy differences
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in FR 2 and CDR3. Highly conserved residues Val42, Gly44, Leu45, Trp47 of conventional VH
domains (Kabat numbering), which participate in hydrophobic interactions with the VL domain,
are replaced with Phe42, Glu44, Arg45, Gly52, respectively, thus reducing hydrophobic
properties (18, 19). Additional differences between VH and VHH domains are observed when
comparing CDR loop size. When compared to conventional VH domains, VHH domains possess
CDR1 and CDR3 loops that are longer in length. In particular, CDR3 is significantly different
with an average VH CDR3 length of 12 and 9 amino acids for human and mouse, respectively
(20), while dromedary VHH CDR3 lengths are 16-18 amino acids (17). The larger hypervariable
loops enlarge the potential antigen binding surface compared to VH domain, and some times
possess a disulfide bond between CDR1 and CDR3 stabilizing the single-domain VHH (20-23).
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Figure 1.3: Cartoon representation of single-domain antibody
VHH, VHH antibody (PDB ID: 2P49): CDR1 (Blue), CDR2
(Green), CDR3 (Red).
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Figure 1.4: Schematic representation of folded VHH domain.
VHH consists of beta strands G, F, C, C’, C” (front) and A, B, E,
D (back). Amino acids of VHH that differ from VH that are
located in the VH/VL interface are indicated (24). CDR1 (Blue),
CDR2 (Green), CDR3 (Red).
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(25). They have been used to detect specific antigens using biosensor chip surfaces (26), to
transmigrate the blood brain barrier (27, 28) and are used in diagnostics, nanosensors and
biotherapeutics (29-32).

Protein/Antibody Engineering

It is frequently desirable to modify a protein to improve its performance for various
biotechnology or medical applications. Such modifications may increase the affinity of the
interaction, enhance protein solubility, or promote ease of protein purification. In 1975,
engineered antibodies were initially produced by in vivo hybridoma techniques with the
production of murine monoclonal antibodies (33). In 1984 the first therapeutic antibody, antiCD3 murine MAb (OKT3) was approved (34); however, it ultimately failed due to production of
elevated levels of anti-murine antibodies in human patients (35). To reduce the unwanted
immune response, chimeric antibodies were generated possessing human constant domains and
mouse variable domains, which resulted in the first chimeric Fab therapeutic antibody in 1994.
Although the new chimeric antibody was less immunogenic then anti-murine MAbs, a human
anti-chimeric antibody response was still observed in patients (36). To further minimize the antichimeric antibody response, humanized antibodies were designed by protein engineering
methods where only the mouse CDR loops responsible for antigen bindings were grafted onto
the human variable domains (37-40).
The invention of site-directed mutagenesis through which altering protein coding DNA
sequence in a site-specific manner was made possible (41, 42). Using this technique recent in
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vitro non-hybridoma procedures have been well developed, which do not require any animal
immunization. These include display methods such as phage (43-46), yeast (47), bacteria (46)
and ribosome (48, 49). Large library sizes and harsh conditions such as a wide range of
temperatures, pH and denaturant conditions are possible using display systems. An important
property of each display system is that the protein being selected is physically linked to genes
coding its sequence.
Using in vitro phage diplay system, large numbers of diverse clones (up to 1010) can be
selected against target of interest and selected clone with specific functions can be obtained (5052). Phage display is used to study protein–ligand interactions, antibody receptor binding sites,
affinity maturation of antibody against the target (51, 53-55). Billions of variants can be
displayed on the surface of the filamentous phage as fusion product to one of the phage coat
proteins (usually pIII, pVIII), resulting in phage particle that encodes the protein and it contains
its gene, resulting in direct link between phenotype (i.e., antibody protein) and genotype (i.e.,
antibody gene). Phage display has been used for protein-protein interactions (56-58), inhibitors
for catalytic site enzymes (59), improving folding and stability (60), epitome mapping for
diagnostics, immunotherapy and vaccine development (61-63), matured antibodies against
harmful pathogen specific targets was used to therapeutically neutralize the pathogens (64, 65)
and naïve antibody libraries to select antibodies with similar homology (66).
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Affinity Maturation
Antibodies of high affinity and specificity are required for therapeutics such as cancer
immunotherapy and molecular biosciences (67-69). High-affinity antibodies are produced
naturally by the immune system using an affinity maturation process that takes place in germinal
centers (GCs) within secondary lymphoid tissues where mature B cells undergo selection of
high-affinity antibodies against target antigens (70-72). Using combinatorial antibody
engineering techniques, a similar process can be mimicked in vitro to generate high-affinity
antibodies (73-76). Antibodies with high binding affinity are of great interest for clinical
applications, due to the fact that a surprisingly large number of commercially available
antibodies demonstrates poor affinity/specificity against their respective targets. Sometimes, in
vivo-derived antibodies require in vitro affinity optimization prior to clinical development, as
enhanced binding generally corresponds with improved clinical efficacy. Prior studies show that
increasing the affinity of an antibody will improve selective tumor delivery (77). Although
affinity plays a significant role for a given therapeutic application, it is often dependent on
biological potency and function. Factors such as immune effector functions, antibody specificity,
stability, clearance may also be important. Nonetheless, these parameters cannot be manipulated
as easily as antibody affinity (78).
In some cases in vitro affinity maturation requires generation of secondary diversified
libraries to improve affinity against the desired target. These approaches to generate affinity
matured antibodie include non-directed methods such as mutator strains, V-gene shuffling, errorprone polymerase chain reaction, and DNA shuffling to more targeted approaches involving
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focused mutations at hotspot positions of the complementarity determining regions (CDRs)
are used s (79-85).

Immunoassays
An immunoassays is an analytical technique widely used across life science
applications. This approach exploits the high affinity and specificity an antibody has to its target.
In 1971, Engval developed first immunoassay called enzyme-linked immunosorbent assay
(ELISA) (86, 87). This approach has become the gold standard detection technique in clinical
settings for measurement of protein antibody targets. In ELISA antigens are immobilized on the
surface of a solid support before incubating with primary antibody that is specific to antigen.
This antibody is linked to an enzyme or secondary antibody. In the presence of substrate, change
in color is associated to presence of primary antibody. Antibodies produced from hybridoma
technologies or protein engineering methods have been utilized as a target protein that can be
immobilized on the surface of solid supports and are extensively used in diverse research like
food assay, bio analytical, (88) clinical diagnostics (89-92).
Recently, there has been great interest in multiplex immunoassay technologies, which
simultaneously detect multiple analytes using polymer beads (93, 94), microtiter plate-based
arrays and surface-functionalized glass etc. Multiplex bead-based immunoassays have been used
to detect biomarkers for various diseases including ovarian cancer (95), coronary artery disease
(96), schizophrenia (97), diabetic macular edema (98). Novel immunoassays using single-photon
fluorescence detection and paramagnetic mircroplates have been used to increase sensitivity of
immunoassay by three orders of magnitude (99).
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Avidin/Biotin System
In 1927 Boas was first to show the requirement for the water-soluble vitamin biotin
(Figure 1.5A) in mammals (100). Mammals depend on dietary intake of biotin from microbial
and plant sources, as they cannot synthesize biotin. Biotin can be covalently tethered to the εamino group of lysine residue using apocaroboxylases (101, 102). Avidin is a protein that can
non-covalently bind biotin. Avidin exists as a homotetramer (Figure 1.5B) and was first isolated
from chicken eggs in 1940 (103). Each monomer of avidin molecule binds to a single biotin
molecule and is the strongest known non-covalent protein-ligand interactions in biology (104).
Streptavidin is a microbial protein from the avidin family, which was isolated from
Streptomyces bacteria (105, 106). Despite having similar structures and functional properties
(107, 108), the primary structure of avidin and streptavidin is only moderately conserved with
amino acid similarity of 41% (109). Streptavidin and avidin proteins are also stable at high
temperatures (110), across a wide range of pH values (111) and can withstand chemical
denaturants (112).
The high affinity and stability of the avidin-biotin interaction has resulted in its use in
numerous life science applications including biochemical, pharmaceutical, bioanalytical and
biophysical applications (113-116). The majority of the avidin-based applications require
biotinylation of target molecules. Chemical biotinylation lacks target selectivity; however,
enzymatic techniques allow site-specific biotinylation, both in vivo and in vitro (117-119). Biotin
ligase enzyme (BirA) effectively biotinylates the lysine residue of the 15 amino acid peptide
called Avitag (120).
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A

B

Figure 1.5: Cartoon structure of biotin molecule and rhizavidin
tetramer A) Stick representation of biotin molecule (244 Da) (PDB
ID: 2C1Q) B) Avidin tetramer (PDB ID: 2AVI).

CHAPTER 2

EXAMINING THE RESIDUE-SPECTIFIC THERMODYNAMIC ORIGINS OF AN
ENHANCED-AFFINITY ANTI-RNASE A VHH ANTIBODY

Introduction

Protein-protein or protein-ligand interactions play a role in nearly every cellular
process, such as DNA replication, transcription, translation, and signal transduction. An
improved understanding of structure/function relationship of such interactions will aid the
discovery of new protein biotherapeutics that target a variety of disease states, such as cancer,
chronic inflammation, and addison disease (121-124). Although insulin was used clinically in
1922 for patients with diabetes (125), it was not until the late 1970’s that there has been a
significant increase in the clinical use of protein-based therapeutics (or biologics). Perhaps the
largest class of protein therapeutics is monoclonal antibodies. Antibodies (or immunoglobulins)
are proteins that are naturally produced in B-cell lymphocytes that are selected to noncovalently
bind foreign, non-“self,” molecules, called antigens. The antibody/antigen interaction is
characterized as a high affinity and specificity interaction, which plays an important role in the
immune response. In addition, the ability to generate antibodies against virtually any antigen
target makes them invaluable as affinity reagents for a wide-range of life science applications.
Immunoglobin G (IgG) is the most prevalent type of antibody in human blood serum and
play a large role in recognizing harmful foreign substances and aiding to neutralize them in
cooperation with additional immune response proteins. As shown in figure 2.1A, the structure of
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IgG consists of two heavy and two light chains. The antigen-binding fragment (Fab), which is
often produced as an independent unit in life science applications, consists of two variable
domains, heavy (VH) and light (VL), as well as two constant domains, heavy (CH) and light
(CL). There are six complementarity determining regions (CDRs) on each Fab, three on each
variable domain (VH and VL) which are flexible loops that participate as the antigen-binding
interface of IgG antibody. In addition to conventional IgG antibodies, the Camelidae family (e.g.,
llamas and camels) produce a fraction of antibodies that possess a heavy-chain-only structure as
shown in Figure 2.1B (10). When compared to conventional IgG antibodies that possess a
VH/VL interface, these heavy-chain-only Camelidae antibodies possess only a single-domain
(VHH) antigen-binding interface. The single VHH domain, with three CDRs, can be expressed
independently, resulting in the smallest possible antibody-binding unit as shown in Figure 2.1C
(126, 127). The single domain VHH possesses a variety of appealing characteristics including
high expression levels, stability across a wide range of temperatures, high chemical stability,
high refolding efficiencies, and resistance to aggregation and protease digestion (128-131).
Consequently, VHH domains have been extensively studied for use in diagnostics, nanosensors
and biotherapeutics (29-32).
Traditionally, high-affinity antibodies have been produced in vivo by animal
immunization (132) and hybridoma techniques (133). While these approaches are nowadays
routine for the field, there are certain limitations, as most pathogenic antigens cannot be injected
into animals without adversely effecting the animal host’s health. To avoid such drawbacks,
recent protein engineering methods including phage (134), bacterial (135), ribosomal (136), and
yeast display (137) systems have been used to generate antibodies in vitro that possess the
desired affinity and specificity. These approaches allow explicit control of selection conditions
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(e.g., temperature, pH, denaturant), which are not possible with traditional in vivo techniques.
The frequent goal of such in vitro screening and selection involves affinity maturation of an
antibody for its specific target. The engergentic and sequence space of in vitro affinity
maturation is vast, consequently, a better understanding of the thermodynamic origins of affinity
maturation may lead to improved methods to generate affinity matured antibodies.

Figure 2.1: Cartoon representation of IgG antibody, heavy-chain
only antibody and single-domain antibody. A) Overlay of IgG
antibody indicating FAB region B) Camelid antibody, devoid of
light chains and CH1 domains, making it approximately half size of
an IgG antibody C) Single-domain antibody VHH.
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Here, we examine the thermodynamic origins of the approximate 100-fold enhanced
affinity of an in vitro affinity matured anti-RNase A VHH antibody (VHH-Mat) compared to the
in vivo generated VHH-Wt. ΔΔΔG° values were calculated from alanine-scanning mutagenesis
performed by Koide at al. (138), allowing examination of the energetic contribution of the nine
substituted interface residues towards affinity maturation. Four of nine residues were found to be
critical for VHH-Mat’s increased affinity as shown in Figure 2.2. Binding and stability studies
were conducted on individual, double, triple, CDR1-only, and CDR3-only variants, where the
mutated residue(s) is changed from the VHH-Wt to VHH-Mat residue. Several trends were
observed, including both positive & negative cooperativity between CDR3 loop residues.
Thermal stability studies were also conducted using circular dichroism. These studies revealed
the substitution of charged residues resulted in TM destabilization. Overall, analysis of these
results suggest new routes that may be taken for the in vitro affinity maturation of antibodies.
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Figure 2.2: Structure of complex between anti-RNase A VHH
antibody and RNase A showing nine residues responsible for
binding. CDR1 colored magenta, CDR3 colored orange.

Materials
Wizard Plus SV Miniprep DNA, Wizard SV Gel and PCR Cleanup purification kits,
enzymes DpnI and Pfu Turbo, Broad Range Protein Molecular markers were purchased from
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Promega (Madison, WI). Isopropyl β-D-1 thiogalactopyranoside (IPTG) purchased from
Denville Scientific (Metuchen, NJ). LB broth, LB agar, 2xYT broth, 2xYT agar, kanamycin,
ampicillin, chloramphenicol, TRIS-HCl, sodium phosphate, sodium acetate, imidazole,
magnesium sulfate heptahydrate, D- (+) -glucose, and guanidine hydrochloride were purchased
from Fisher Scientific (Fair Lawn, NJ). Oligonucleotides, bovine pancreatic RNase A, dimethyl
sulfoxide (DMSO, ≥99. 9%), ethylenediaminetetraacetic acid (EDTA), sodium dodecyl sulfate
(SDS), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), bromophenol blue,
deoxycholic acid, oxidized glutathione (GSSG), and reduced glutathione (GSH) were purchased
from Sigma (St. Louis, MO). TMB buffer, streptavidin/horseradish peroxidase conjugate was
acquired from Thermo Scientific (Rockford, IL). Nitrocellulose paper was obtained from Maine
Manufacturing, LLC (Stanford, ME). T4 DNA ligase, T7 DNA polymerase, T4
phosphonucleotide kinase, and dNTPs were obtained from New England Biolabs (Ipswich, MA).
QiaPrep Spin M13 kits were purchased from Qiagen (Germantown, MD).

Vectors

Dr. Shohei Koide (University of Chicago, Chicago, IL) generously provided the pHFTVHHR expression vectors (139) containing the wild-type gene for anti-RNase A VHH antibody
and the affinity-matured anti-RNase A VHH antibody clone. The pHFT-VHHR vectors are T7driven expression vectors included VHH genes that contained an N-terminal (His) 6-Flag-Tev
purification tag. A T7 expression vector contained with the gene for a (His)6-tobacco etch virus
(TEV) protease was generously donated by Dr. Anthony Kossiakoff (University of Chicago,
Chicago, IL).
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Cells

All cells, including XL1-Blue, CJ236, and BL21 (DE3) E. Coli were purchased from
Stratagene (La Jolla, CA).

Methods

Generation and Production of Anti-RNase A VHH Mutants
Using the pHFT-VHHR vector (Figure 2.3) containing the gene of anti-RNase A VHH-Wt
(figure 2.4), individual mutants were produced by site-directed mutagenesis techniques including
Quick Change and Kunkel Mutagenesis (140).
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Figure 2.3: Gene map of pHFT-anti RNase A VHH –Wt created
with SnapGene.
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Figure 2.3: Amino acid sequence of anti-RNase A VHH (cABRN05). The number scheme is derived from the amino acid
numbering of cAB-RN05 crystal structure (PDB ID: 1bzq).
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Quickchange Site-Directed Mutagenesis

In 1998, Stratagene (La Jolla, CA) developed the Quickchange Site-Directed
Mutagenesis procedure to insert or delete individual mutations into double stranded DNA
(dsDNA) using a pair of complementary primers. Primers must be between 25 and 45 bases in
length with predicted melting temperature greater than or equal to 78°C. An estimate of the Tm
can be calculated using the following formula:

Tm = 81.5+0.41(%GC) − 675/N −%mismatch

(Eq 2.1)

Where, N is the number of bases in the primer, %GC is the percentage of guanine and cytosine
bases within primer and % mismatch is the whole number representing the mismatch between
primer and parent DNA. The mutations (whether deletion, substitution, or insertion) are located
in the middle of the primers with at least 10-15 bases on both sides. Primers should start and end
with either guanine or cytosine and should include at least 40% GC content.
The Quickchange reaction mixture consists of a forward and reverse primer (Table 2.1),
the parent dsDNA, dNTPs, and Pfu Turbo DNA polymerase, which are subjected to several
rounds annealing and extensions in a thermo cycler. The first step in the thermo cycler is to heat
the reaction mixture at 95°C for 30 seconds to denature the DNA strands, then, in a second step,
cooled to 55°C for 1 min to anneal the primers on the parent DNA. The third step includes
heating to 68°C for 5 mins for nonstranded-displacing ction of Pfu Turbo DNA polymerase
enzyme activity and DNA elongation. The reaction cycle is repeated sixteen times to increase the
mutant-containing DNA. The reaction mixture is further digested by DpnI for 1 hr at 37°C,
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which results in digestion of methylated, nonmutated parent DNA template. The digested
DNA template is transformed into XL-1 blue E. coli cells using a heat shock method and plated
onto respective antibiotic-containing LB agar. Mutagenesis of the DNA is confirmed by sending
plasmid DNA from individual clones for sequencing at the University of Chicago Sequencing
Center.
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Table 2.1: Oligonucleotide primers designed for quick change
mutagenesis. Anti-RNase A VHH-Wt was used as parent DNA
VHH
Oligonucleotide Primer (5’ → 3’)
Mutation

A28P

F 5’ –CGCAGCAAGCGGTTACCCATACACCTACATCTA-3’
R 5’ –TAGCATGTAGGTGTATGGGTAACGCTTGCTGCG-3’

Y29W

F 5’ -CGCAGCAAGCGGTTACGCATGGACCTACATCTACATGG-3’
R 5’ -CCATGTAGATGTAGGTCCATGCGTAACCGCTTGCTGCG-3’

Y101D

F 5’ -CTGCGCAGCAGGTGGTGACGAACTGCGTG-3’
R 5’ -CACGCAGTTCGTCACCACCTGCTGCGCAG-3’

E102A

F 5’ -CAGCAGGTGGTTACGCACTGCGTGACCG-3’
R 5’ -CGGTCACGCAGTGCGTAACCACCTGCTG-3’

R104V

F 5’ -GGTGGTTACGAACTGGTTGACCGTACCTACGG-3’
R 5’ -CCGTAGGTACGGTCAACCAGTTCGTAACCACC-3’

D105A

F 5’ -GTTACGAACTGCGTGCTCGTACCTACGGTCA-3’
R 5’ -TGACCGTAGGTACGAGCACGCAGTTCGTAAC-3’

R106T

F 5’ -GTTACGAACTGCGTGACACTACCTACGGTCAATGGG-3’
R 5’ –CCCATTGACCGTAGGTAGTGTCACGCAGTTCGTAAC-3’

T107R

F 5’ -CGAACTGCGTGACCGTCGCTACGGTCAATGG-3’
R 5’ -CCATTGACCGTAGCGACGGTCACGCAGTTCG-3’

Q110R

F 5’ -TGACCGTACCTACGGTCGTTGGGGTCAAGGCACC-3’
R 5’ -GGTGCCTTGACCCCATGCACCGTAGGTACGGTCA-3
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Kunkel Mutagenesis
Kunkel mutagenesis is a classic method for introducing mutations, either single base
pairs or large insertions, deletions or substitutions into a plasmid DNA sequence (140). A
schematic of the Kunkel mutagenesis method is shown in Figure 2.2. In the first step, doublestranded DNA (dsDNA) is converted to single-strand uracilated DNA (ssDNA) template. This is
accomplished by using plasmid dsDNA with a F1 origin, which permits the generation of single
strand replication upon infection with helper phage. Initially, the dsDNA containing the F1
origin is transformed into CJ236 cells. The E.Coli. CJ236 strain (dut-/ung-) is deficient of the
enzyme deoxyuridine triphosphate (dut-), resulting in the incorporation of uracil in place of
thymine in DNA due to the degradation of deoxyuridine triphosphate (dUTP), and is deficient of
uracil N-glycosilase (ung-), which prevents the subsequent excision of uracil from DNA (141).
The transformed E. coli CJ236 cells are plated onto LB-agar containing Ampicillin (100 µg/mL),
for selection of the pHFT-VHHR plasmid DNA, and chloramphenicol (5 µg/mL) for selection
of E.coli CJ236 cells. A single colony from the O/N 37°C plate to inoculate a 2 mL 2xYT
Amp/Cm culture, which is incubated with shaking at 37°C until mid-log phase (OD600 = 0.5-0.7),
which typically take 4-7 hrs. Mid-log phase cultures containing poly-uracilated plasmid DNA are
infected for one hour with 2 µL of helper phage M13K07 (final concentration of 1010 phage/mL).
The culture is then added to 200 mL of 2xYT CM/Amp/Kan, maintaining CJ236/Plasmid
DNA/M13K07 antibiotic selection. After 16 hrs of incubation at 37°C, the cultures are
centrifuged at 8500 × g for 10 min at 4°C. The supernatant is saved and 1/5 volume of sterile
20% (w/v) PEG 8000 with 2.5 M NaCl is added, vigoursly mixed 3 to 4 times and placed on ice
for 1 hr to precipitate the phage that encapsulate the single strand polyuracilated template. The
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phage particles are isolated by centrifugation at 8,500 × g for 20 min at 4°C. The supernatant
is discarded slowly without disturbing the soft, white phage particle precipitate. A pipette is used
to remove any leftover supernatant. The precipitate is re-suspended with 1/200 volume (based on
starting culture) of nuclease free water. Single strand DNA is isolated using Qiagen Qiaprep spin
M13 kit.
Kunkel primers pairs should ideally contain 15 complimentary bases on each side of the
site of mutagenesis. Similar to Quickchange mutagenesis, the primers should begin and end with
guanine or cytosine bases to aid primer/template recognition. When using multiple primers in a
single Kunkel reaction, care should be taken so that the primers do not overlap and ideally posess
at least 6 to 9 bases between adjacent primers for successful multi-primer annealing. Covalently
closed circular (ccc)-DNA heteroduplex is created in a three-step process. In the first step,
primers are phosphorylated by T4 polynucleotide kinase, ATP and DTT at 37°C for 30 min.
When using multiple primers in a Kunkel reaction, all primers should be phosphorylated
individually.
Phosphorylated primers are incubated with ssDNA at 90°C for one minute, 50°C for
three minutes, and ice for two minutes. All these steps are done quickly with no layover times
between temperature conditions. Finally, T7 DNA polymerase and T4 DNA ligase are added and
incubated for 16 hrs at room temperature to synthesize a complementary strand. PCR clean up
reaction was performed using Promega Wizard PCR clean up system before transforming into E.
coli XL1 blue cells by heat shock. XL1 blue cells excise the uracilated parent strand from the
ccc-DNA heteroduplex to incorporate the mutations by repairing plasmid. Mutagenesis was
confirmed by sending individual clones for sequencing (University of Chicago Sequencing
Center).
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Electroporatio
n
Into CJ236

Figure 2.5: Schematic representation of Kunkel Mutagenesis. The figure was obtained from:
http://2011.igem.org/Tem:Washington/Celiacs/Methods.html.
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Table 2.2: Oligonucleotide primers designed for Kunkel mutagenesis.
VHH
Parent
Oligonucleotide Primer (5’ → 3’)
Mutation
DNA
A28P/Y29W

Anti-RNase A
VHH A28P

5’ -CCATGTAGATGTAGGTCCATGCGTAACCGCT
TGCTGCG-3’

Y101D/T107R

Anti-RNase A
VHH Y101D

5’ -CCATTGACCGTAGCGACGGTCACGCAGTTCG-3’

E102A/R104V

Anti-RNase A
VHH E102A

5’ -CCGTAGGTACGGTCAACCAGTTCGTAACCACC-3’

Y101D/T107R/
Q110R

Anti-RNase A
VHH
Y101D/T107R

Y28W/Y101D/
T107R/Q110R

Anti-RNase A
VHH
Y101D/T107R
/Q110R

5’ -GGTGCCTTGACCCCATGCACCGTAGGTACG
GTCA-3

5’ -CCATGTAGATGTAGGTCCATGCGTAACCGC
TTGCTGCG-3’

Protein Expression and Purification of Mutants

The pHFT–VHHR and pet21a vectors containing anti-RNase mutants were transformed
into E. Coli strain BL21 (DE3). A 5 mL Lb (Kanamycin 30 mg/mL for pHFT-VHHR/
Ampicillin 100mg/mL for pet21a) culture was started from a single colony and grown overnight.
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After overnight incubation at 37ºC, 1 mL of O/N subculture was added to 50 mL of culture
and incubated until mid-log phase. Next, 15 mL of subculture was added to 1 L culture and
incubated at 37°C until it reaches OD600= 0.6. Gene expression was induced using 1 mM IPTG
and incubated overnight at 20°C with shaking. Cells were harvested by centrifuging the cultures
at 8,000 rpm for 15 min. The supernatant was disposed and the pellet was frozen (-20°C). The
frozen pellet was resuspended into 10 mM Tris pH 8.0 and sonicated for four 30 sec on/off
cycles using Branson Digital Sonifer (Branson Ultrasonics Corporation, CT, USA).
Centrifugation at 12,000 rpm for 20 min. allowed isolation of the insoluble fraction, which
included the VHH inclusion bodies. The inclusion body pellet was subjected to three wash steps
including: (1) 2% (w/v) deoxycholic acid/50 mM Tris/5 mM EDTA/pH 8.0, (2) ddH2O, and (3)
10 mM Tris pH 8.0. After every wash step, samples were centrifuged at 8,000 rpms for 20 min.
and supernatants were discarded. Inclusion body pellets were resupended and solubilized in 50
mL of unfolding buffer (6M guanidine-HCl, 50 mM disodium hydrogen phosphate, 300 mM
NaCl, 2.0 mM reduced glutathione, 0.2 mM oxidized glutathione at pH 7.4) and centrifuged for
20 min at 12,000 rpms to clarify the solution. The soluble, unfolded protein was refolded through
drop-wise addition of solution into 500 mL refolding buffer (20 mM Tris, 2.0 mm reduced
glutathione, 0.2 mm oxidized glutathione, pH 7.4) at 4°C while stirring. The refolded protein
solution was clarified by centrifuging and then purified using a 5 mL Histrap HP column (GE
Healthcare, Piscataway, NJ) with a 14-column volume (70 mL) linear gradient between running
buffer (20 mM imidazole, 50 mM disodium hydrogen phosphate/HCl, 500 mM NaCl, pH 8.0)
and elution buffer (500 mM imidazole, 50 mM disodium hydrogen phosphate/HCl, 500 mM
NaCl, pH 8.0). The low concentration of imidazole in the wash buffer is commonly used to
minimize unwanted binding of bacterial host cell proteins, while the higher concentration of
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imidazole in the elution buffer is sufficient to elute the his-tagged protein. The single peak
corresponding to a particular anti-RNase A mutant was further purified on a HiLoad 26/60
Superdex 75 prep grade size exclusion column. To remove the His-flag-Tev purification tag, a
20:1 w/w ratio of VHH:TEV protease was incubated O/N at 4°C. The VHH protein, free of the
His Tag, was separated using a Histrap HP column by collecting the flow through. A final
Superdex 75 size exclusion column was run as a final polishing step of the anti-RNase A VHH
protein.

Instruments

Isothermal Titration Calorimetry

Isothermal titration calorimetry (ITC) can be used to directly measure the heat of
interaction between protein-protein or protein-small molecules (142). Modern ITC instruments
can measure heats as low as 0.1 µcal. A single ITC experiment can allow the determination of
the equilibrium constant (KB=1/KD), change in enthalpy (ΔHº), change in entropy (ΔSº), change
in Gibbs free energy (ΔGº), and the binding stoichiometry (n).
The heat of interaction is used as a probe of the extent of binding, as one component of
interaction is titrated into another, the resulting heat is proportional to the the concentration of
complex formed at any moment of the titration and thus related to the equilibrium binding
constant (KB). With knowledge of the KB, using equation 2.2, we can determine the change in
Gibbs free energy, ΔGº:
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ΔG° = −RTlnKB

(Eq.

2.2)

where T is the experimental temperature of the known KB value and R is the gas constant. With
known ΔG°, ΔH°, and T, the change in entropy ΔS° for the interaction can be calculated from
equation (2.3).

ΔS°= (ΔH° – ΔG°)/T

(Eq 2.3)

The change in heat capacity, ΔCP, between the free state to bound states and can be calculated by
determining the change in enthalpy over a range of temperatures using equation (2.4)

ΔCP = (∂ΔH) /(∂T)P

(Eq 2.4)

Prior to each ITC experiment, both the VHH variant and RNase A are dialyzed overnight at 4°C
against 4 L of 150 mM NaCl and 20 mM sodium phosphate buffer, pH 7.4. Protein
concentrations were determined by UV absorbance at 280 nm using Beer’s Law in equation
(2.5) (143, 144).

A = εbc

(Eq 2.5)

34
where A is the absorbance, b is the path length, c is the concentration in molarity, and ε is the
extinction coefficient, which was estimated using equation 2.6:

ε280 ( M−1. cm−1) = 5,500 NTrp + 1,490NTyr + 125Ncys

(Eq 2.6)

where ε280 is the molar extinction coefficient in units of M−1 cm−1 at 280 nm, NTrp is the number of
tryptophan residues, NTyr is the number of tyrosine residues, Ncys is the number of cystines.
For 1:1 binding stoichiometry, the concentration of sample in the syringe will typically be 10-fold
higher than the concentration of the protein in the cell. Ideal protein concentrations are determined by
c-value:

c = Kb [M]

(Eq 2.7)

where Kb is the binding constant of the protein interaction and M is the concentration of
macromolecule in molarity. The ideal c-value should in the range of 5-20 (145).

Data Analysis

Let us call the species in the syringe as A and the species in the cell as B. After making
an injection of A, the resulting concentration of free A, [A], and the complex, [AB], in the cell
changes. The produced heat (whether released or absorbed) is associated with the amount of
binding that occurs, i.e., the change in the fraction of B bound. For a simple, one-site binding
model, the heat for the ith injection Qi is related to the change in enthalpy by the following
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equation (2.8):

Qi = [B]tot V0 (Fi –Fi-1) ΔH

(Eq 2.8)

Where V0 is the volume of the cell before first injection and F is the fraction of B bound. The
subscripts of F refer to the injection. The change in the volume with relation to injection of A is

F = [AB]/[B tot]

(Eq 2.9)

The above equation provides a relationship between free and the amount of complex between A
and B being formed at each injection. We need to relate F to KB, where

KB = [AB]/([A][B])

(Eq 2.10)

It is also known that [A] = [Atot] – [AB] and [B] = [Btot]–[AB], substituting these relationships
into above results in equation (2.11):

KB = [AB]/(( [Atot] – [AB]) – ([B] = [Btot]–[AB]))

(Eq 2.11)

Rearranging equation (2.9) results in the following quadratic relationship

[AB]2–([Atot] +[Btot] + 1/KB)[AB]+ [Atot][Btot] = 0

(Eq 2.12)
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The real root of this equation then gives a value for [AB] in terms of the known concentrations
[Atot] and [Btot]. Thus, the fitting of a series of injections provides the value of the equilibrium
constant (146, 147).
All ITC experiments were performed at 25°C using a Microcal VP-ITC titration
calorimeter (Microcal, LLc, Northampton, MA) and all protein samples are dialyzed overnight in
4 L of PBS buffer (20 mM sodium phosphate, 150 mM NaCl, pH 7.4) to insure buffer matching.
1-2 mg of RNase A (Sigma- Aldrich, St. Louis, MO) was dissolved and diluted in PBS buffer.
Concentrations were determined using spectroscopy. Molar extension coefficients for various
VHH mutants were determined using the Edelhoch or Pace methods, while 9440 M-1cm-1 was
the 280 nm extinction coefficient for RNase A. All absorbance measurments were measured in
triplicate. Experiments were conducted with VHH mutants injected into cell with concentrations
ranging from 15-40 µM and RNase A concentrations between 1.5 to 4 µM inside the cell. ITC
experiments are programed with 28, 10 µl injections with 200 s between injections and a stirring
speed of 307 rpm. The initial 2 µl injection was discarded to account for dilution across the
needle during equilibration. Data was analyzed using Origin.

Circular Dichroism
Circular dichroism (CD) measures differences in the absorption of left-handed circularly
polarized light and right-handed circularly polarized light.

(ΔA = AL –AR)

(Eq 2.12)
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where ΔA is differential absorption or dichroism, AL and AR are the absorbance of left and right
circularly polarized light, respectively. Generally this value is reported in terms of ellipticity (θ)
with units of degrees. The relationship between differential absorption (ΔA) and ellipticity (θ)
(148-150) is:

θ = 32.98 ΔA

(Eq 2.13)

CD signals are obtained by absorption of radiation. Every structure has its own spectral band,
which are assigned to different structure features of a molecules. Proteins exhibit circular
dichroism based on the asymmetric centers and structures (primary, secondary and tertiary
structures). More importantly, secondary structures exhibit electronic transitions states, such as
n→π* and π →π*. The n→π* transition is broad but weak in the UV region around 220 nm and
the more intense π →π* transition is around 190 nm. Different types of protein secondary
structure (α-helix, β-sheet, type 1 β-turn, extended 31-helix) have their own characteristic CD
absorption spectra in the far UV region. The tertiary structure of proteins has fingerprint region,
in particular, signals near UV 260-320 nm are the result of aromatic amino acids (tryptophan,
tyrosine and phenylalanine) (149).
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Figure 2.6: Far-UV CD spectra showing various types of secondary
structure. Solid line, α-helix; long dashed line, anti-parallel βsheet; dotter line, type 1 β-turn; cross dashed line, extended 3 1helix or poly (Pro) II helix; short dashed line, irregular structure
(149).

Far UV CD absorption spectra can give quantitative estimates of secondary structure.
However, it is an ideal technique to study conformational changes such as those that may occur
when changing experimental parameters such as pH, temperature and binding of ligands. When
examining protein unfolding, the extent of the conformational change can be analyzed using CD
to understand the stability of the folded state of the protein (150, 151). CD can also used for
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ligand binding and drug design, as the binding of the ligands can result in changes in the
conformation of the protein (152).
All CD experiments were run with an Aviv Instruments circular dichroism spectrometer
model 215 (AVIV Biomedical Inc., Lakewood, NJ) with protein samples dialyzed against 4 L of
20 mM sodium phosphate dibasic heptahydrate, 150 mM sodium chloride, pH 7.4, overnight.
Protein concentrations were determined using UV-Vis and appropriate dilutions were performed
in dialysis buffer. Wavelength scans containing 10 µM protein concentration were carried out at
25°C from 200 to 260 nm with bandwidth of 1.00 nm, using a 1 x 10 mm Suprasil quartz 300
cuvette with polytetrafluoroethylene stopper. Additionally, temperature denaturation experiments
were carried out at 207 nm from 25 to 85°C with temperature band of 0.20°C. Following the
completion of the thermal scan to 85°C, the sample was returned to 25°C and incubated for 15
min. Triplicate post-melt wavelength scans were performed. TM values were determined with
Origin Labs using a two-state unfolding models.

Results

Binding Thermodynamics of VHH-Wt and VHH-Mat Complexes

We are trying to understand the thermodyanmic origins of enhanced affinity for an in
vitro affinity matured anti-RNase A VHH Antibody (VHH-Mat), which possesed a binding
affinity ~100-fold greater than the original in vivo generated VHH-Wt (153). To more fully
understand the molecular driving forces for the enhanced binding affinity, one must look past KD
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and ΔGB. The binding thermodynamics (including ΔH and ΔS) of the VHH/RNase A
interaction was determined by ITC. Figure 2.7 shows a typical VHH ITC titration. Analysis of
the ITC binding profile allows determination of ΔHB, KD, and n, and calculation of ΔGB, and ΔSB
using the Gibbs equation.

RTlnKD = ΔGB(T) = ΔHB(T) - TΔSB (T)

(Eq 2.14)

where R is the universal gas constant (1.98588 cal K-1 mol-1), T is the obsolute temperature, ΔGB
is free energy of binding, ΔHB(T) is the difference in enthalpy of binding, and ΔSB is the
difference in entropy of binding.
The VHH-Wt KD, determined by ITC, was 16 ± 2 nM, which is consistent with
previously published data of 23 ± 3 nM determinded by yeast surface display experiments.
Figure 2.7 shows VHH-Mat ITC titration, where the equilibrium dissociation constant was
estimited to be less than 1 nM, preventing exact determination of KD, due to detection limitations
of the calorimeter. To determine the actual KD of VHH-Mat, displacement (or competitive) ITC
experiments were performed by Robert James Hoey IV, as shown in Figure 2.7.
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Figure 2.7: ITC titration showing VHH into RNase A. A) VHH-Wt.
B) VHH-Mat direct titration. C) Mat displacement titration (154).
Table 2.3 shows all the thermodynamic values. ΔGB, and ΔSB values were calculated using
the Gibbs equation.

Table 2.3: Binding thermodynamics of VHH-Wt and VHH-Mat
determined by ITC thermodynamic values.
KD ,

ΔGB,

ΔHB,

-TΔSB,

nM

n

kcal/mol

kcal/mol

kcal/mol

Wt

16 ± 2

0.98 ± 0.01

−10.64 ± 0.06

-10.6 ± 0.4

-0.2 ± 0.4

Mat

0.3 ± 0.1

1.00 ± 0.02

-13.1 ± 0.2

-20.1 ± 0.3

7.0 ± 0.4
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Compared to VHH-Wt, VHH-Mat displayed ~100-fold increase in affinity (ΔΔGB = -2.5
kcal/mol, calculated by ΔGB,VHH-Mat – ΔGB,VHH-wt) and is similar to previously determined KD of
the VHH-Mat/RNase A interaction determined by yeast display by Koide et al. (153). Relative to
the parent protein VHH-Wt, the enhanced affinity of VHH-Mat is through a very favorable
enthalpy contribution, which overcomes a large unfavorable entropy of binding.

Predicting Residue Specific Contribution for Enhanced Affinity

To understand the role of the nine residues introduced during affinity maturation of
VHH-Mat, Koide, et al. performed alanine-scanning mutagenesis (153). Alanine scanning
mutagnesis is a technique widely used to determine hot-spot residues important for binding (155159). Despite the fact this technique can reveal the energetic consequences of the absence of a
residue, it does not provide detailed insight into the importance of the residue for affinity
maturation.
To provide detailed insight into the potential energetic benefit of affinity matured residue
substitutions, a ΔΔΔGº analysis was performed. This approach examined differences in alanine
scanning mutagesis between the VHH-Wt/RNase A & VHH-Mat/RNase A complexes. The
ΔΔΔG° was calculated using the following relationship:

ΔΔΔG° = ΔΔG°Mat,Ala – ΔΔG°Wt,Ala

(Eq 2.15)
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where ΔΔG°Mat,Ala and ΔΔG°Wt,Ala are the ΔΔG° values calculated from alanine scanning
mutageneis for all the single mutants of CDR1 and 3, between the VHH-Mat and VHH-Wt
variants, respectively (139). Using a ΔΔΔG° cutoff value of greater than 1 kcal/mol (which
represents an approximate >five fold increase in affinity), four (Y29W, Y101D, T107R, Q110R)
of the nine residue substitutions were identified as key residues for enhanced affinity as shown in
Figure 2.8. The remaining five mutations appear as either spectator residues or possess smaller
energetic contributions beyond what can be detected using the ΔΔΔG° analysis.

Binding Thermodynamics using ITC

Isothermal Titration Calorimetry (ITC) was used to determine the energetic role of
residues for affinity enhancement. Table 2.4 shows the binding thermodynamics for all the nine
single mutants.
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Figure 2.8: ΔΔΔG° analysis to predict the residues responsible for
affinity maturation. A) ΔΔΔG ° graph of the CDR1 and 3 mutations
between Wt and Mat, where ΔΔΔG° = ΔΔGMat, Ala – ΔΔGWt, Ala
B) Top view of the Mat paratope with the four ° mutations
highlighted in spheres (154).
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Table 2.4: Binding thermodynamics of VHH mutants determined
by ITC
KD,
ΔGB,
ΔHB,
nM

n

Wt

16 ± 2

0.98 ± 0.01

Mat

0.3 ± 0.1

A28P

kcal/mol

-TΔSB,

kcal/mol

kcal/mol

−10.6 ± 0.1

-10.6 ± 0.4

-0.2 ± 0.4

1.00 ± 0.02

−13.1 ± 0.2

-20.1 ± 0.3

7.0 ± 0.4

6±2

0.96 ± 0.01

−11.2 ± 0.2

-9.6 ± 0.3

-1.6 ± 0.3

xY29W

5.4 ± 0.4

0.97 ± 0.01

−11.3 ± 0.1

-12.0 ± 0.1

0.7 ± 0.0

Y101D

23 ± 3

1.00 ± 0.03

−10.4 ± 0.1

-12.0 ± 0.1

1.6 ± 0.0

E102A

8.0 ± 1.2

0.98 ± 0.01

−11.0 ± 0.3

-10.3 ± 0.1

-0.9 ± 0.1

R104V

3.7 ± 0.3

1.03 ± 0.02

−11.5 ± 0.1

-9.11 ± 0.1

-2.3 ± 0.1

D105A

17 ± 4

0.99 ± 0.01

−10.6 ± 0.1

-10.6 ± 0.1

0 ± 0.3

R106T

21 ± 3

0.95 ± 0.01

−10.5 ± 0.1

-11.1 ± 0.2

0.6 ± 0.3

T107R

600 ± 100

0.95 ± 0.01

−8.5 ± 0.1

-8.1 ± 0.2

-0.4 ± 0.3

Q110R

6±1

0.98 ± 0.04

−11.3 ± 0.1

-11.4 ± 0.2

0.2 ± 0.1

Based on the binding energetic results obtained from ITC, it was observed that VHHMat achieved an ~2.5 kcal/mol increase in affinity compared to VHH-Wt. Examination of the
additive contributions of the nine single mutations revealed a ~0.7 kcal/mol increase in binding
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energy, which was obtained by the sum of (ΔGWt –ΔGA28P) + (ΔGWt – ΔGY29W) + (ΔGWt –
ΔGY101D)+ (ΔGWt – ΔGE102A) + (ΔGWt –ΔGR104V) + (ΔGWt –ΔGD105A) + (ΔGWt –ΔGR106T) + (ΔGWt
–ΔGT107R) + (ΔGWt –ΔGQ110R). The difference between the VHH-Wt and VHH-Mat variants (–
2.5 kcal/mol) was not equal to the simple additive contributions of the individual mutants. While
there are examples of multiple mutations that contribute in an additive fashion (160, 161), this
finding suggests the existence of non-additive interactions between residues. These non-additive
interactions that contribute to changes in the overall binding free energy may be less then or
greater then the wild type interactions.
Only ΔΔΔG° values for Y29W and Q110R showed an increased affinity, as well as
similar energetic profile to VHH-Mat with a more enthalpically favored binding process
overcoming an entropic penalty as shown in Figure 2.9. Y101D shows a slightly decreased
affinity and energetic profile similar to VHH-Mat. T107R shows the profile opposite of VHHMat, along with lowest (weakest) observed KD, with an unfavorable enthalpic contribution and
favorable entropic contribution. To understand the potential additive and cooperative effects of
binding, double (A28P/Y29W, Y101D/T107R, E102A/R104V), triple (Y101D/T107R/Q110R)
and quadruple (Y29W/Y101D/T107R/Q110R) mutants were produced and the binding
thermodynamics were obtained using ITC.
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Figure 2.9: Binding thermodynamics of VHH mutants determined
by ITC; Scale of darker green showing a greater increase in affinity
than compared to Wt, decrease is in affinity shown in red; Positive
cooperatively in blue and Negative cooperitivity in yellow.

Binding Thermodynamics of CDR1

VHH variant A28P, which was not anticipated to show an increase in binding affinity
based on alanine scanning analysis, showed an increased binding affinity with favorable entropic
contributions and no change in enthalpic contributions. As previously discussed above, Y29W
showed a similar profiles as VHH-Mat. A double mutant A28P/Y29W clearly showed an
additive thermodynamic contribution between the two residues, as show in Figure 2.10
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Figure 2.10: Thermodynamic profiles of CDR1 VHH mutants.

Binding Thermodynamics of CDR3:
Across seven single CDR3 mutants, three of the mutants, E102A, R104V, and Q110R
were observed to enhance the binding affinity. Although enhanced affinity for Q110R was
expected (based on the ΔΔΔG° analysis), E102A and R104V also showed significant enhanced
affinity. Binding energetics of E102A and R104V exhibited favorable enthalpic and entropic
contributions. As enhanced affinity was not expected a double mutant for E102A/R104V was
generated. As compared to the single mutants E102A and R104V, the binding thermodynamics
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of the double mutant E102A/R104V showed a non-additive contribution (negative
cooperativity). Individual mutants Y101D, D105A, and R106T showed no significant difference
in binding. D105A had a small enthalpic loss but a small increase in entropy. R106T displayed a
small enthalpic gain, but a small entropic loss. Surprisingly, the T107R variant showed a profile
with a dramatic loss of binding affinity, with the least favorable enthalpy and slightly favorable
entropy. Based on the VHH-Mat structure, D101 and R107 are closesly positioned within the
VHH interface, which suggests an intramolecular salt bridge between the two residues. To
explore its energetic contribution, double mutant Y101D/T107R was produced. Compared to
VHH-Wt, the double mutant possessed an increase in affinity (~0.6 Kcal/mol) through a
marginally more favorable enthalpic gain and an entropic penalty. The Y101D mutant possessed
a higher affinity, but very little difference in both the enthalpy and entropy of binding. These
results confirm that the slight increase in affinity is due to positive, cooperative interactions
between Y101D and T107R residues. This interaction overcomes the loss of binding energy from
the single T107R, a change which likely causes a destabilization of CDR3 and subsequent drop
in binding affinity. A triple mutant Y101D/T107R/Q110R (ΔΔΔG° mutants of CDR3) was
made to explore the presence of additional cooperative interactions; however, the binding
thermodynamics suggest a simple additive effect in between the between double mutant
Y101D/T107R

and Q110R with enhanced favorable enthalpic contributions and increased

unfavorable entropic contributions similar to the thermodynamic profile of VHH-Mat.
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Figure 2.11: Thermodynamic profiles of CDR3 VHH mutants.

Thermal Stability Using Circular Dichrosim (CD)

CD was used to examine the thermal stability of the VHH-Wt, VHH-Mat and their
mutants. Thermal melts were performed by measuring the loss of the CD signal at 207 nm. The
CD signal was collected from 25°C to 85°C, which was sufficient to obtain a post transition
baselines.
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Table 2-5: TM values for VHH mutants determined by
the CD
WT
Mat
Y29W
2M
Y101D
E102A
R104V
D105A
R106T
T107R
Q110R
3M
4M

TM °C
69.3 ± 0.2
62.4 ± 0.1
66.7 ± 0.3
69.0 ± 0.3
65.3 ± 0.1
69.1 ± 0.3
70.6 ± 0.2
72.6 ± 0.3
72.0 ± 0.6
57.3 ± 0.1
65.7 ± 0.3
64.6 ± 0.2
65.1 ± 0.4

As shown in Table 2.5, thermal stability experiments allowed determination of the melting
temperature (Tm), which revealed VHH-Mat was destabilized compared to the parent protein,
VHH-Wt, with a 6.9°C decrease in TM. Of all the mutants, T107R shows the most significant
decrease

in

TM

(12°C).

Y29W,

Y101D,

Q110R,

Y101D/T107R/Q110R,

and

Y29/Y101/T107R/Q110R all show TM destabilization compared to VHH-Wt. On the other hand,
variants that removed a charged residue, D105A, R106T, and R104V, resulted in increases in the
TM values, relative to VHH-Wt.
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Stabilization Destabilization

Figure 2.12: Bar graph showing TM melts. 2M indicating
E102A/R104V; 3M indicating Y101D/T107R/Q110R and 4M
indicating Y29/Y101/T107R/Q110R mutants.
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Discussion

Structure/Thermodynamic Relationships of VHH Variants
VHH-Mat displays a more favorable enthalpy of binding compared to VHH-Wt.
Generally, changes in enthalpy are due to the formation or loss of non covalent bonds, such as
hydrogen bonds, ionic bonds and van der Waals interactions (162), while changes in entropy are
due to changes in conformational entropy, solvation (e.g., loss of the favorable apolar surface
area in the interface) and changes in the ordering of structured waters in between a proteinprotein interface (163).

CDR1
The A28P mutation involves replacing a small, nonpolar hydrophobic alanine residue
with a nonpolar hydrophobic proline, which results in a favorable binding energy with a slight
enthalpic penalty and favorable entropic contributions compared to VHH-Wt. Figure 2.10 shows
a structural overlay of the CDR1 residues from VHH-Wt and VHH-Mat which illustrates
proline’s conformationally restricted side chain might influence (i.e., enhance) the interaction
with neighboring residue 29 (whether Tyr or Trp) or simply minimize conformational entropy of
the CDR1 loop. The later is supported the A28P entropy profile. Proline may interact favorably
with the nonpolar tyrosine due to the hydrophobic affect and the CH-π interaction between the π
aromatic face of tyrosine and polarized CH bonds of proline resulting in favorable entropic
contributions (164).
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Figure 2.13: A) B) Overlay of VHH-Wt and VHH-Mat showing
CDR1 residues A28, Y29 from VHH-Wt and 28P, 29W from
VHH-Mat, shown in different angles.

The Y29W mutation, which replaced a nonpolar tyrosine with a bulkier nonpolar
tryptophan, resulted in an increase in the binding energy with a favorable enthalpic contribution
and a non-favorable entropic contribution. This result is somewhat surprising, as the the Y29W
substitution involves additional nonpolar burial of surface area as the Trp-29 packs against an
extended Lys-61 sidechain as shown Figure 2.14. The observed interaction appears at a poor
angle for a potential cationic-π interaction, an interaction type that is often observed in protein-
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protein interfaces (165) as shown in figure 2.14. Reasons behind slight loss in entropy is not
clear. The A28P/Y29W double mutant resulted in favorable enthalpic and entropic contributions
through the apparent additive contributions of each substitution.

Figure 2.4: 29W residue of VHH-Mat colored in green interacting
with K61 from RNase A colored in orange

CDR3
The Y101D variant, included a subsitution of a polar tyrosine to a negatively charged
aspartic acid resulted in a slight decrease in binding affinity with favorable enthalpic
contributions and unfavorable entropic contributions, similar to the general profile of VHH-Mat.
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Structurally, the Y101D mutation results in formation of a new hydrogen bond between the
side chain of Asp-101 with the mainchain of Thr-70 as shown in Figure 2.15.

Figure 2.15: Overlay of VHH-Wt and VHH-Mat showing hydrogen
bond formation beginning between E102 and Y101 and 101D and
T70 of RNase A.

The E102A mutation substitutes a negatively charged glutamic acid with a neutral,
nonpolar alanine residue, which resulted in a slight increase in binding affinity with unfavorable
enthalpic and favorable entropic contributions. The R104V mutation substitutes a positively
charged arginine with a neutral, nonpolar valine residues, which resulted in an increase in

57
binding affinity. Similar to E102A, an enthalpic loss is compensated with favorable entropy
resulting in increased binding affinity. This may be attributed to new hydrophobic packing
interactions that are available to Val-104. The D105A mutation, which replaces a negatively
charged aspartic acid with a nonpolar neutral alanine, did not alter the binding affinity, with
negligible changes in the enthalpy and entropic terms. R106T, which replaces a positively
charged arginine with a polar thereonine, resulted in no change in binding affinity with a slightly
more favorable enthalpy compensated by an unfavorable entropic contributions. T107R, which
replaces a polar thereonine with a positively charged arginine, resulted in a suprisingly large loss
of binding affinity

compared to VHH-Wt (38-fold), due to an unfavorable enthalpy and

favorable entropy. The significant loss in the enthalpic component may be due to the disruption
of an intricate hydrogen bonding network where the sidechain hydroxyl of T107 interacts with
neighboring backbone atoms (figure 2.15). Favorable entropy might be due to increased
confirmational flexibility due to loss of hydrogen bonding network. Q110R, which replaces a
polar glutamine residue with a positively charged arginine, resulted in a profile simlar to VHHMat, with a slight increase in affinty due to more favorable enthalpic and less favorable entropic
contribution, as compared to VHH-Wt. Potential reasons behind the slight change enthalpic and
entropic contributions are not apparent from the crystal structure.

Double Mutants E102A/R104V and Y101D/T107R

Enhanced affinity was not expected for single mutants E102A and R104V based on
ΔΔΔG° the analysis. However, the double mutant, E102A/R104V, revealed negative
cooperativity with a slightly reduced affinity. The enthalpic and entropic contributions are
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comparable to single mutants E102A and R104V. The most likely rationale for the observed
non-additive enegetic contribution is that the Glu-102/Arg-104 pair participated in an
intramolecular salt bridge in VHH-wt. On the other hand, non-additive contributions (positive
cooperativity) were observed with the simultaneous presence of residues 101D and 107R. This
suggests the formation of a salt bridge between the aspartic acid and arginine pair. The double
mutant possessed a large increase in binding affinity, with a favorable increase in enthalpy and a
slight decrease in entropy relative to the T107R mutant. When compared against Y101D, the
double mutant has a ~4 fold higher affinity, with little difference in enthalpic and entropic
contributions.
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Figure 2.16: VHH-Wt, hydroxyl threonine-107 forming intricate
hydrogen bonding with backbone atoms.

Y101D/T107R/Q110R
Triple mutant Y101D/T107R/Q110R (ΔΔΔG° mutants of CDR3) was made to explore
the presence of additional cooperative interactions; however, the binding thermodynamics
suggest a simple additive effect in between the between double mutant Y101D/T107R and
Q110R with enhanced favorable enthalpic contributions and increased unfavorable entropic
contributions similar to the thermodynamic profile of VHH-Mat.
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Y29W/ Y101D/T107R/Q110R
ΔΔΔG° mutants were made to explore the presence of additonal cooperative interactions
between CDR1 Y29W and the CDR3 Y101D/T107R/Q110R; however, the binding
thermodynamics suggest a simple additive effect between CDR residues. This observation is in
agreement with what may be expected from the affinity maturation procedure, where the initial
selection explored full amino acid diversity within the individual CDR1 and CDR3 loops. The
four residues identified by the ΔΔΔG° analysis, when together, possessed a favorable enthalpic
and unfavorable entropic contributions similar towards binding, similar toVHH-Mat as shown in
Figure 2.17. However, the Y29W/Y101D/T107R/Q110R variant does not account for all the
energetic enhancment in the Gibbs free energy between VHH-Mat and VHH-Wt (~2.5 kcal/mol)
as predicted by ΔΔΔG° analysis. Consequently, the remaining difference in Gibbs free energy
must collectively come from the small contributions of A28P, E102A, and R104V.
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Figure 2.17: Thermodynamic profiles of ΔΔΔG° mutants.

Discussion of Stability Studies:

Hydrogen bonding and ionic interactions play an important role in protein thermostability
(166). The mutants R104V, D105A and R106T, all involve substitutions that include the
replacement of a charged residue with a neutral residue. R104V, which replaces a positively
charged arginine with a neutral, nonpolar valine residue, exhibited a 1.3°C increase in TM
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stabilization compared to Wt. Interestingly, the R104 side chain appears to be involved in a
salt bridges with nearby Glu-102, which is in close proximity (3.4 A°). Consequently, the origins
of the enhanced Tm are not clearly understood. D105A, which replaces a negatively charged
aspartic acid with a neutral, non polar alanine residue exhibited a 3.3°C increase in TM compared
to VHH-Wt. Despite residue D105 being oriented away from the interface, it appears in a salt
bridge with FW residue Arg-45. Alanine replacement will disrupt this D105/R45 salt bridge.
R106T replaces a positively charged arginine residue with a polar neutral threonine in a highly
positively charged patch (including R45 and R104), which resulted in a 2.7°C increase in TM
stabilization likely due to decrease in electrostatic repulsion. E102A involves the replacement of
a negitively charged glutamic acid with a nonpolar alanine, which resulted in a negligible (0.2°C
decrease) change in TM compared to VHH-Wt. E102 forms a hydrogen bond with Tyr-101 and
salt bridge with Arg-104. Despite these interactions, the lack of appreciable change in Tm suggest
they are not energetically critical for the free VHH structure..
The remaining three mutants Y101D, T107R and Q110R result in TM destabilization. All
three mutants involve replacement of a non-charged residue with a charge residue. Y101D
exhibited a 4°C decrease in TM relative to VHH-Wt, which replaces a neutral, polar tyrosine
with a negatively charged aspartic acid. Asp-101 appears likely to result in electrostatic repulsion
with nearby negatively charged Glu-102. T107R, exhibited significant drop in Tm (12°C ). This
destabilization is likely due to the elimination of backbone hydrogen bonds with R104, Y101 and
Y108. Also, the introduction of a positive charge into a highy positively charged region will
result in electrostatic repulsion, as shown in figure 2.18. Q110R exhibited a 3.6°C decrease in TM
relative to VHH-Wt, interestingly, there are no obvious structural reason to suggest the observed
destabization upon replacement of a polar uncharged glutamine with a postively charged arginine.
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Figure 2.18: Cartoon showing interface of VHH-Wt consisting of
charged residues resulting in TM destabilization.
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Conclusions

ΔΔΔG° values of nine relevant interface residues were calculated from alanine-scanning
mutagenesis, which revealed that four of nine residues were most critical for VHH-Mat’s
enhanced affinity. Thermodynamic binding and stability studies were conducted using
isothermal titration calorimetry (ITC) and circular dichroism (CD) on individual, double, and
triple mutants, as well as isolated CDR1 or CDR3 loop variants, where wild-type residues were
replaced with the VHH-Mat residues. These studies revealed the enhanced binding energy (~2.5
kcal/mol) of VHH-Mat was achieved through both additive and non-additive contributions as
shown Figure 2.20A. Non-additive contributions were observed for two salt bridge interactions,
Y101D/T107R (formation, positive cooperativity) and E102A/ R104V (loss, negative
cooperativity). Overall, the non-additive energetic components were more significant (~70%
non-additive vs. ~30% additive) towards the enhanced binding as shown in Figure 2.20B. When
comparing inter-CDR loop interactions (CDR1 and CDR3), only additive contributions were
observed. The observed thermodynamic signature of VHH-Mat enhanced binding appears to
directly follow the nature in which CDR1 and CDR3 variants were initially derived, which
included full randomization of each individual CDR before combining a reduced subset (i.e.,
positivive clones) for joint CDR1/3 screening and selection. Thus, the approach greatly
diminished chances for inter-CDR loop non-additive contributions. These findings reveal the
important role that localized, intramolecular interactions may have on enhanced affinity.
Furthermore, the detailed dissection of the binding thermodynamics may help shape library
design with the goal of developing affinity-matured antibodies.
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Figure 2.4: A) Bar graph showing the contributions of additive
and non additive accounting for difference Gibbs free energy
observed from Mat and Wt. B) Pie graph showing additive and
non-additive contributions.

Chapter 3

ENGINEERING AND CHARACTERIZATION OF A BIVALENT VHH COMPLEX
USING AVIDIN-BIOTIN MEDIATED INTERACTIONS

Introduction
Antibodies can be generated to bind a wide range of target molecules, each typically
possessing high specificity and affinity for their specific target, resulting in their broad use in
detection and immunodiagnostic assays. Monoclonal antibodies are often replaced with smaller
antibody fragments, including Fabs, single chain antibody fragments (scFv) and single-domain
antibodies (sdAbs), due to their ease of production. To improve antibody affinity towards a
particular target, a variety of affinity maturation methods have been employed (73, 74, 167-170).
Increased valency is one way of increasing functional affinity against densely populated antigens.
Figure 3.1 illustrates a model of multi-valent binding scenario. In general, multivalent antibodies
can provide valuable tools for biomedical research, diagnosis and therapy. To date, several
approaches have been used to increase valency of scFv antibody fragments, including leucine
zippers (171-173), p53 tetramerization sequence (174), peptide linkers (175, 176), and single
cysteine residues (177). However, each method possesses its own drawbacks, such as inadequate
expression and solubility, which introduces limits for their further development.
Site-specific in vivo biotinylation was initially described by Schatz (1993) and was
popular in the late 1990’s for applications in the assembly of MHC class I (multivalent)
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tetramers on phycoerythrin-streptavidin for flurometry analysis of T lymphocyte (178).
Similarly, streptavidin was used for tetramerization of scFv cysteine variants, which allowed
site-specific chemical biotinylation (177). An alternate approach involved genetically fusing
ScFv with a streptavidin monomer, which was expressed in E. coli and produced a multivalent
affinity reagent when the streptavidin monomers assembled into their physiological tetramer
structure (179). These streptavidin-driven multivalent complexes were not limited to scFv, a
recent study of a Fab-Streptavidin tetramer showed higher observed affinity due to multivalency
(180). Relatively smaller single-domain antibodies (sdAbs) have a number of advantages when
compared to conventional antibodies due to their small size and low structural complexity. They
can be expressed at high levels and high solubility in bacterial E. coli systems. Previous studies
showed that sdAbs expressed as multimers had improved binding capabilities and detection
limits (181-185).
The high-affinity avidin–biotin complex represents the strongest known non-covalent
interaction, with a dissociation constant estimated in the femtomolar range (Kd ~ 10-15 M). In
addition, it is one of the most used reagents for a wide range of applications, such as clinical
diagnostics, labeling, targeted drug delivery, nanotechnology, and biotechnological applications
(186-189). Four identical subunits of avidin form a tetrameric complex, where each monomer
has a biotin-binding site (figure 3.2 A). While almost all avidin-like proteins such as streptavidin
and bradavidin (190) possess a tetrameric structure, rhizavidin is an exception, which is observed
as a homodimer in solution (figure 3.2 B).
Applications of the avidin/biotin system frequently involve using the avidin protein to
“capture” a protein of interest that has been tagged with one or more biotin molecules. This
tagging, or biotinylation, of a target protein is performed using two main approaches. The first is
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chemical biotinylation, which typically involves random amine coupling of the biotin or biotin
analog to the protein. Due to its random nature, this method of coupling can effect the function
of the targeted protein, such as reducing antibody affinity or may even result in complete
inactivation of the function and/or loss of native structure (191). A second method of
biotinylation uses an enzyme-directed approach. Biotin protein ligase (BirA) is an enzyme that
catalyzes the formation of an amide bond between the carboxyl group of biotin and the ε-amino
group of a lysine residue within a 15 amino acid length peptide sequence (known commercially
as Avitag).
Here, using a rhizavidin biotin system and a sdAb (VHH) antibody, a bivalent sdAb
reagent was engineered with the aim to increase functional affinity of the sdAb. Initally, the
model sdAb, anti-RNase A VHH, was engineered to have a C-terminal Avitag sequence. The
resulting anti-RNase A VHH-Avitag variant was first enzymatically biotinylated and then
assembled into a bivalent 2:1 sdAb/rhizavidin complex. The bivalent single-domain complex
was confirmed by size exclusion chromatography and SDS-PAGE. Surface plasmon resonance
was used for quantitative evaluation of binding association and dissociation, which revealed at
least a ~100-fold higher apparent affinity for the bivalent sdAb complex.
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Figure 3.1: Higher functional affinity was observed for multivalent
system.
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Figure 3.2: A) Schematic ribbon representation of streptavidin
tetramer, each monomer binding single biotin molecule (PDB ID:
3WYP) B) Ribbon representing rhizavidin dimer (PDB ID: 3EW2).
All molecular graphics figure were generated using PyMOL (192).
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Figure 3.3: Cartoon structure of anti-RNase A VHH antibody –
RNase A complex. RNase is shown in spheres, anti-RNase A VHH
antibody shown in ribbon structure.
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Materials and Methods

Generation of Anti-RNase A VHH – AV

Starting with the gene for an anti-RNase A VHH (Y101D/T107R mutant, described in
Chapter 2) within a pHFT-VHHR vector, Kunkel Mutagenesis (140) was performed to introduce
a 15 amino acid C-terminal Avitag peptide (GLNDIFEAQKIEWHE) (120). The following
oligonucleotide was used to generate the the C-terminal Avitag anti-RNase A VHH, anti-RNase
A VHH–AV.

5’-GTGGTGCTCGAGCTAGGTCTGAACGACATCTTCGAAGCTCAGAAAATCGAATGGC
ACGAAGCTGCTTACGGTTAC-3’

DNA sequencing was used to verify insertion of Avitag peptide on the C-terminus of the antiRNase A VHH (Y101D/T107R mutant) gene. Top Gene technologies (Montreal, Canada)
synthesized an E. coli codon-optimized gene for rhizavidin and subcloned the rhizavidin gene
into a pKP300 drop-out phagemid vector (193). The vector was kindly provided by Brain K. Kay
(University of Chicago, Chicago, IL)
Anti- RNase A VHH-AV Expression and Purification

The anti-RNase A VHH–AV plasmid DNA was transformed into E. coli strain BL21
(DE3) by heat shock and plated on LB agar plates containing 100 µg/mL Ampicilin. A single
colony was used to inoculate 5 mL Lb broth containing 30 µg/mL kanamycin, which was
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incubated overnight at 37°C with shaking. The next morning, 1 mL of O/N subculture was
added to 50 mL of culture. Once the culture reached mid-log phase growth, 15 mL of subculture
was added to 1 L culture and incubated at 37°C until it reached mid-log phase (OD600= 0.6).
Expression was then induced using 1 mM IPTG and the culture was allowed to incubate
overnight at 20°C with shaking. Cells were harvested by centrifugation at 8,000 rpms (11325 x
g) for 15 mins. The supernatant was disposed and the pellet was stored at -20°C.
The frozen pellet was resuspended in 10 mM Tris pH 8.0 and sonicated for four 30 sec
on/off cycles using Branson Digital Sonifer (Branson Ultrasonics Corporation, CT, USA).
Centrifugation at 12,000 rpm for 20 min to allow isolation of the insoluble fraction, which
included the VHH inclusion bodies. The inclusion body pellet was subjected to three wash steps
including: (1) 2% (w/v) deoxycholic acid/50mM Tris 5mM EDTA/pH 8.0, (2) ddH2O, and (3)
10mM Tris pH 8.0. After every wash step, samples were centrifuged at 8,000 rpms for 20 min.
and supernatants are discarded. Inclusion body pellets were resupended in 50 mL of unfolding
buffer containing (6M guanidine- HCl, 50mM disodium hydrogen phosphate, 300mM NaCl, 2.0
mM reduced glutathione, 0.2 mM oxidized glutathione at pH 7.4) and centrifuged for 20 min at
12,000 rpms. The soluble, unfolded protein was refolded through drop-wise addition of solution
into 500 mL refolding buffer (20 mM Tris, 2.0 mm reduced glutathione, 0.2 mm oxidized
glutathione, pH 7.4) at 4°C while stirring. The refolded protein was clarified by centrifuging and
then loaded on a Histrap HP column. The soluble fraction was first purified and concentrated on
a 5 mL Histrap HP column (GE Healthcare, Piscataway, NJ) using a 14-column volume (70 mL)
linear gradient between running buffer (20 mM imidazole, 50 mM disodium hydrogen
phosphate/HCl, 500 mM NaCl, pH 8.0) and elution buffer (500 mM imidazole, 50 mM disodium
hydrogen phosphate/HCl, 500 mM NaCl, pH 8.0). Imidazole at low concentration in wash buffer
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are commonly used to minimize the unwanted binding of host cell proteins and higher
concentration of imidazole in elution buffer was used to elute histag protein by replacing it with
higher concentration of imidazole in elution buffer.

Biotin Ligase (BirA) Expression and Purification

(His)6 -BirA-pET21a (+) plasmid DNA was transformed into E. Coli strain BL21 (DE3)
by heat shock and plated on LB agar plates containing 100 µg/mL Ampicillin. A single colony
was used to inoculate 5 mL Lb broth containing 100 µg/mL Ampicillin, which was incubated
overnight at 37°C. One milliliter of O/N subculture was added to 50 mL of LB/Amp culture.
Once the culture reached mid-log phase growth, 15 mL of the subculture was added to 1 L of
LB/Amp and incubated at 37°C until OD600= 0.6. Expression was induced using 100 µg/mL
IPTG and incubated at 30°C with shaking for 3 hrs. The lower temperature improved the folding
and efficiency of BirA. Cells were harvested by centrifuging the cultures at 8000 rpms for 15
mins. Supernatant was disposed and pellet was stored at -20°C. Histrap IMAC was used to purify
biotin ligase, similar to the anti-RNase A VHH-AV procedure (Chapter 2).

In vitro Enzymatic Site-Specific Biotinylation of C-terminal Avitag VHH

VHH-Avitag was dialyzed in 10 mM Tris-HCl at pH 8.0 before biotinylation, as the
presence high concentration of salt (from the previous size exclusion purification step) will
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reduce the biotinylation efficiency. For every 10 nmol of VHH-Avitag substrate (at 40 µM
concentration), the final reaction mixture contained 2.5 µg of Biotin ligase (birA) enzyme, 100
µM biotin, 10 mM ATP, and 10 mM magnesium acetate. The reaction was incubated for 3 hrs at
30°C allowing biotinylation of the epsilon amino group of the Avitag lysine (figure 1.1). Post
reaction, the sample was run on a Superdex 75 size exclusion column to separate free biotin,
ATP, and birA enzyme.
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Figure 3.4: Chemical amino acid sequence representation of
avitag peptide and molecular illustration of BirA-mediated
biotinylation of lysine residue in the presence of ATP and
biotin (194).

Biotin Quantification Using HABA

Site-specific biotinylation of C-terminal Avitag VHH was confirmed by a HABA (4’hydroxyazobenzene-2-carboxylic acid) assay developed by Green (195). HABA can be used to
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estimate the mole-to-mole ratio of biotin to protein. The biotinylated protein was added to a
solution containing a mixture of HABA and avidin. As biotin has higher affinity for avidin then
compared to HABA, biotin is replaced with HABA resulting in a decrease in absorbance at 500
nm, which is directly proportional to the displaced avidin. The unknown amount of biotin present
in a solution can then be quantified by measuring the absorbance of the HABA-avidin solution
before and after addition of biotinylated protein.
A 96-well microplate was used to minimize the amount of sample being used in the
HABA assay. The HABA solution (0.01 M) was prepared using 0.01 M NaOH. Next, 4.8 µL of
HABA solution was added to 40 µL streptavidin (249 µM for monomer) and PBS buffer (pH
7.4) was added to a final reaction volume of 80 µL. The absorbance of the HABA/Avidin
complex was measured at 500 nm and recorded as value A1. Next, 16 µL of 14.7 µM biotinylated
VHH sample was added to the well containing the HABA/Avidin solution and mixed thoroughly
before measuring the absorbance A2 after signal remains constant for at least 15 seconds at 500
nm. Using the enzymatic in vitro biotinylation, 98.7 % of Avitag protein was biotinylated.

Rhizavidin Expression and Purification

The pKP300-Rhizavidin plasmid DNA was transformed into E. Coli strain BL21 by heat
shock and plated on LB agar plates containing 100 µg/mL Ampicillin. A single colony was used
to inoculate 10 mL Lb broth containing 100 µg/mL Ampicillin and was incubated overnight at
37 °C at 235 rpm. The next morning, 10 mL of O/N subculture was added to 500 mL of low
phosphate media containing 100 µg/mL ampicillin and incubated at 30 °C for 18-20 hrs at 250
rpm shaking. One liter of low phosphate media was prepared with the following components:
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ammonium sulfate (3.57 g); sodium citrate dihydrate (0.71 g); potassium chloride (1.07 g);
yeast extract (5.36 g); and Hy-Case SF casein acid hydro lysate (5.36 g) from bovine milk
(Sigma-Aldrich). The solution's pH was adjusted to 7.3 with KOH. The media was autoclaved,
cooled, and MgSO4 (1 M, 7 mL) and glucose (1 M, 14 mL) were added.
Cells were harvested by centrifuging the cultures at 8000 rpms for 15 mins. Supernatant
was disposed and pellet can be stored at -20°C. Cell pellets were resuspended in 10 mM Tris,
pH 8.0, and lysed by sonication on ice for a total of two minutes. Cell lysate was centrifuged for
20 minutes at 12,000 rpm to separate insoluble and soluble fractions at 4°C. The clarified cell
lysate was used for protein purification. Rhizavidin was purified with a 5 mL GE Histrap nickel
IMAC column similarly as anti-RNase A VHH. Finally the rhizavidin was purified on a
Superdex-75 size exclusion column using 20 mM Tris/HCl, 300mM NaCl, pH 8.0. Following the
final step of purification, a 1 L expression typically yielded 30-40 mg of purified rhizavidin
protein.
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Figure 3.5: Schematic ribbon representation of structure of
rhizavidin homodimer (PDB ID: 3ew2).
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Bivalent Construct Assembly

Rhizavidin and biotinylated anti-RNase A VHH-AV was incubated in a 1:2 molar ratio
at room temperature for 1 hr to produce a ~63 kDa bivalent complex, as shown in Figure 3.4

Figure 3.6: Cartoon picture showing bivalent complex, singledomain antibody VHH (green) with C-terminal avitag peptide,
biotin (violet), rhizavdin dimer (light blue).
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Surface Plasmon Resonance

A Reichert SR7500DC dual channel SPR instrument (Reichert, Depew, NY) was used
for all SPR measurements. The carboxymethyl dextran hydrogel sensor chip (Reichert Cat#
13206066) was used for the experimental surface. Running buffer, HBS-P, consisted of 10 mM
HEPES, 150 mm NaCl, and 0.005% Tween 20. All the buffers were filtered using 0.2 µm filter
and degassed for at least for 1 hr. Succinimide esters were activated by injection of an
equivalent mixture of freshly prepared 0.2 M 1-Ethyl-3- [3-dimethylaminopropyl] carbodimide
hydrochloride (EDC) and 0.1 M N- hydroxysuccinimide (NHS) for a 8 min exposure at a flow
rate of 20 µl/min. Immediately following, 250 µl of 400 µg/mL RNase A in 10 mm sodium
acetate, pH 5.0, was injected at a flow rate of 20 µl/min to allow random amine coupling to the
first flow cell. Remaining free succinimidyl esters were deactivated by an 8 min injection of 1
M ethanolamine at a flow rate of 20 µl/min. Approximately 5000 µRIU of RNase A was
immobilized on the high density carboxymethyl dextran surface.
All SPR kinetic measurements are performed at a flow rate of 50 µl/min, Triplicate runs
with 2 minutes on-rate and 7 minutes off-rate injections were performed at five different
concentrations ranging from 50 nM to 50 pM. Running buffer was used for dilutions of sample
to minimize sample mismatch, which can lead to signal inconsistencies. Regeneration of the
surface was performed by injection of a 2:1 mixture of 100 mm glycine, pH 2.0 and ionic
cocktail (1.83M MgCl2, 0.92M urea, and 1.83M Gdn-HCl) at 50 µl/min for 15 sec. Buffer
injections were performed before and after each sample injection. The binding sensorgrams were
double-referenced by subtracting the signal of the reference cell and the closest buffer blank
injections. All the data were analyzed in a 1:1 Langmuir binding model using Scrubber 2.
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Figure 3.7: The image of carboxymethyl dextran hydrogel from
Reichert (13206066). Flexible non-cross linked brush like structure
extending 100 to 200 nm from the surface are shown on the gold
plated surface. Source:http://www.reichertspr.com/products/sensorchips/carboxymethyl-dextran-hydrogel-surface-sensor-chip-part13206066/?back=products.

Binding Kinetics

The reaction between immobilized protein (B) and analyte (A) can be used to follow
pseudo-first-order kinetics (196, 197). As the flow of analyte is constantly restored, the free
concentration of analyte is known and constant during association time. The interaction between
an immobilized protein (B) and soluble analyte (A) results in formation of complex (AB) for the
reversible reaction shown equation 1:
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ka
A + B ⇌ AB
kd

(Eq. 3.7)

where ka and kd are association and dissociation rate constants, respectively. The rate of
formation of the complex, AB, at time t can be written as

d[AB]/dt = ka [A][B] – kd [AB]

(Eq. 3.8)

[B] = [B]0 – [AB]

(Eq. 3.9)

After reaction time, t,

Where [B]0 is the concentration of B at t = 0, results in

d[AB]/dt = ka [A]([B]0 – [AB]) – kd [AB]

(Eq. 3.10)

The observed signal, R, is directly proportional to the formation of complex AB and the
maximum signal, Rmax, is proportional to the active protein concentration immobilized on the
surface resulting in equation 3.11

dR/dt = ka C (Rmax – R) – kd R

(Eq. 3.11)
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where ka and kd are association and dissociation rate constants, respectively. The rate of
formation of the complex, AB, at time t can be written as

dR/dt = ka CRmax – (kaC + kd) R

(Eq. 3.12)

where ka is the association rate constant, C the molar concentration of the analyte in solution, kd
the dissociation rate constant, R the amount of bound analyte in RU
Considering the above equation in the form of y = mx + C, plot between dR/dt and R yields the
slope (kaC + kd) denoted by ks, integrated rate association rate equation

  

R = (r0/Ks) (1-e-Ks (t-t0))

(Eq. 3.13)

Where t0 is start time for the association, t is the time in seconds and ks = (kaC + kd). During
dissociation the analyte is replaced by buffer, resulting in a free concentration of analyte of zero,
consequently, the complex will start dissociating and the rate of dissociation of the formed
complexes, AB, is described by

dR/dt = -kdR

(Eq. 3.14)

Integration of the rate of dissociation into equation 3.14 results in

R = R0 . e-kd (t-t0)

(Eq. 3.15)
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where R0 is the response at the arbitrary starting time of the dissociation. The rate constants of
association and dissociation are related to the equilibrium dissociation constant by

KD = kd / ka

(Eq. 3.16)

Results and Disscusions
Although a majority of the approved clinical antibodies consist of a full–length IgG
format, their large size may possess certain limitations, like difficulty in tissue penetration and
inefficiency reaching certain cryptic antigen sites (198-200). To evade these problems, smaller
antigen binding fragments such as Fab, Fv, and scFvs can be used to in place of full-length Abs.
Similarly, VHH, the single variable domain from heavy-chain-only antibodies from the
Camelidae family possess antigen binding properties comparable to Fab, Fv, scFv and Mab, yet
are even smaller (~15 kDa). These VHH domains are small, stable, highly soluble, exhibit low
aggregation, and can be expressed in large quantities (201-203) VHH domains typically possess
faster blood clearance, which limit certain applications of unmodified VHH domains (204, 205).
Enhancing functional affinity by increasing binding valency is one approach to overcome
monovalent VHH sdAbs that possess low affinity. Avidity or functional affinity represents the
observed binding strength of a multivalent antibody for its antigen. Compared to a monovalent
system, multimerization increases the availability of multivalent binding sites on an antigen.
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Converting sdAbs into multivalent system may, in particular, increase their functional affinity
by decreasing the dissociation rates due to multiple adjacent binding events, which is particularly
advantageous for surfaces desely populated with antgen. Previously, multimer VHH sdAbs were
assembled to form either a pentamer, by linking them to the B-subunit of E. coli verotoxin (131),
or a decamer, by linking two of the verotoxin B-subunit (206). The size of the Ab-based drug
molecules is an important factor for renal excretion and consequently systemic clearance. Halflife times of an antibody molecule correlates with its size, as the threshold for glomerular
filtration was estimated to be ~60-65 kDa. While full length IgG molecules are too large to be
filtered by the kidneys, smaller VHH domain and scFv fragments have shorter half-lives in the
range of 0.5-2 hrs (207).

In vitro Biotinylation of Avitag sdAb

Through an enzymatic reaction (using BirA), a biotin molecule can be covalently
attached to the lysine residue of the Avitag peptide, whether in vivo or in vitro. Notably, in vivo
biotinylation efficiency can vary from experiment to experiment and the biotinylated protein also
gradually loses its biotin during storage (208). Here, in vitro biotinylation was used to biotinylate
the C-terminal Avitag sdAb. The biotinylation on the Avitag sdAb was confirmed using HABA.

Size Exclusion Chromatography To Characterize The Bivalent Complex Formation

The monovalent VHH-AV domain was converted into a bivalent complex after incubation of the
biotinylated VHH-AV with Rhizavidin in 2:1 molar ratio (room temperature for 1 hr). The
mixture of the biotinylated anti-RNase A VHH-AV and rhizavidin were run on a sephacryl 200
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size exclusion chromatography column to evaluate the formation of a bivalent complex. In
addition, a control experiment was performed using non-biotinylated anti-RNase A VHH-AV
and rhizavidin. Size exclusion chromatography is a separation technique based on the solution
size of the protein. As shown in figure 3.8, the complex mixture resolves as major peak peak,
corresponding to the anticipated bivalent complex size (63 kDa), along with and a small second
peak, consistent with excess unreacted anti-RNase AVHH AV (16 kDa). The Control experiment,
which included non-biotinylated VHH-AV, clearly matches the elution time of the unreacted
anti-RNase A VHH AV peak.

88

~31kDa
~63kDa
~16kDa

Figure 3.8: Chromatogram showing biotinylated anti-RNase A
VHH-AV (-rhizavidin complex ~63kDa; black), mixture of
rhizavidin (~31kDa) and non-biotinylated anti-RNase A VHH-AV
(~16kDa) separated individually (red)
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SDS-PAGE Gel to Characterize Bivalent System

Due to the high stability and high affinity of rhizavidin/biotin systems, SDS-PAGE
analysis can be used to evaluate the molecular species present in the sdAb/Rhizavidin complex.
Samples of complex, Rhizavidin dimer, and anti-RNase A VHH-AV, all, with and without
reducing agent β-marcapetoethanol (BME) or heating were run on a 4-20% SDS-PAGE gel (see
Figure 3.9). Lane 1 clearly shows the formation of complex with approximate molecular weight
around ~63 kDa, Lane 2 has a band observed at ~31 kDa for Rhizavidin dimer, lane 3 has a band
observed at ~16 kDa for anti-RNase A VHH-AV. Reducing agent in first three lanes didn’t show
any significant change in observations. Lane 4,5,6 had samples heated at 80°C for 10 min before
loading the samples, which resulted in disrupting the rhizavidin dimer to a monomer, lane 4,6
showed no changes. Lane 7,8,9 without any reducing agent showed a similar trend as with
reducing agent.
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Figure 3.9: A coomassie-stained 4-20% gradient SDS-PAGE gel.
Lane1, 2, 3 containing complex, rhizavidin dimer, anti-RNase A
VHH-AV respectively containing β-marcapetoethanol (BME) for
reduced conditions. Lane 4, 5, 6 containing complex, rhizavidin
dimer, anti-RNase A VHH-AV with heating at 80°C for 10 min and
BM. Lane 7, 8, 9 containing complex, rhizavidin dimer, anti-RNase
A VHH-AV without reducing conditions.

SPR-Derived Binding Kinetics for the Monovalent and Bivalent Complex

The binding kinetics of the monovalent and bivalent antibody complex was evaluated
using SPR. Target antigen, RNase A, was covalently attached to the sensor chip. A range of
concentrations of either the monovalent or bivalent complexes were injected over the surface.
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Figure 3.10 shows the SPR sensograms of the monovalent sdAb (Figure 3.10A) and bivalent
sdAb (Figure 3.10B) interactions. Both monovalent and bivalent systems were evaluated using
Standard 1:1 Langmuir fit to facilitate a comparison of apparent affinities, which allowed
extractions of the apparent association (ka) and dissociation (kd) rate constants, as shown in the
Table 3.1. Based on the standard 1:1 binding model, there was a negligible differences in the
observed association rate constants (ka) for the monovalent and bivalent systems; however, a
significant difference was observed in the dissociation rate constant (kd), The bivalent system did
not exhibit any appreciable dissociation. To better understand dissociation of bivalent system, a 5
hour elution run was performed (figure 3.11). Similarly, the bivalent complex did not show
appreciable dissociation, suggesting a significant effect of the multivalent complex avidity. This
suggests that enhanced affinity is driven mostly by the dissociation constant which is not
uncommon for a multivalent system. A multivalent single-domain antibody, specific to T-cell
receptor (HLA-A2), was created from human cartilage oligomeric matrix protein resulting in
pentavalent and decavalent sdAbs, which exhibited negligible dissociation against the T-cell
recepetor (HLA-A2) (185). The binding dissociation constants, KD, was approximately 4.1 nM
for the monovalent VHH and N/D* (not determined) for bivalent systems. Half-life dissociation
time for monovalent system was approximately around 1241 Seconds ( ~20 mins) and half life
dissociation time for bivalent system was not determined (N/D*).
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Figure 3.10: SPR sensograms. A) The anti-RNase AVHH-AV interaction and B) The bivalent complex
interaction. The red lines represent the global fit to the
data using a bimolecular Langmuir model

Table 3.1: Binding kinetics of monovalent anti-RNase A VHH and
bivalent anti-RNase A VHH determined by SPR
N/D*: not determined
-1

ka’ M .s

-1

kd’ s

-1

KD, nM

Monovalent

1.14 ± 0.01 × 105

4.74 ± 0.01 × 10-4

4.17 ± 0.01

Bivalent

2.17 ± 0.01 × 105

N/D*

N/D*
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Figure 3.11: SPR sensogram showing binding behavior of bivalent
complex and RNase A for 5 hr off rate

Table 3.2: Binding kinetics (5 hr dissociation ) of bivalent antiRNase A VHH determined by SPR ; N/D*: not determined
-1 -1

Bivalent

-1

ka’ M .s

kd’ s

2.19 ± 0.01 × 105

N/D*

KD, nM

N/D*
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Table 3.3: Dissociation half life t1/2, sec
t1/2, Sec
Monovalent

1241.0 ± 172.0

Bivalent

N/D*

Conclusions
A bivalent single-domain antibody complex was obtained through in vitro biotinylation
of a C-terminal Avitag sdAb and complex formation with rhizavidin. The 2:1 complex was
confirmed by size exclusion chromatography and SDS-PAGE. Surface plasmon resonance was
used for quantitative evaluation of the binding association and dissociation kinetics, suggesting
at least a 100-fold higher apparent affinity for bivalent sdAb complex. The difference was mostly
attributed to the dissociation (kd) values. These results are similar other multivalent system where
the avidity effect became apparent in decreased kd values (209, 210). The significant decrease in
off-rate for bivalent system stems from the bivalent nature of the engineered complex and avidity
effect, where both sdAb are required to be unbound to dissociate from the surface. The same
strategy can also be use to create bispecific molecules that can target two target antigens
simultaneously. Bispecific antibodies can result in applications such as effector functions,
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cytotoxic cells or delivery of immunodiagnostics (211). The ability to produce high apparent
affinity sdAbs from low affinity sdAbs may have a wide range of practical applications,
including immuno-diagnostic and immune-therapeutic applications. Multimerization of antibody
fragments may also improve serum half life, as a tetravalent scFv of the parcarcimona
monoclonal antibody CC49, which recognizes tumor associated glycoprotein, TAG-72, showed
significant improved biodistribution compared to the monovalent scFv (212).

Chapter 4
BUILDING A SEQUENCE DATABASE OF NON-HYPERVARIABLE
LOOP CDR4

Introduction
Monoclonal antibodies have been produced in vivo using animal immunization (213) and
hybridoma technology (214), targeting a range of molecules, including proteins, carbohydrates
and low molecular weight compounds (215, 216). Initially, this antibody generation process
requires multiple cycles of immunization, which can take several months. At this point, a
hybridoma may be generated, which involves the fusion of a B-lymphoblast cell, which
expresses a specific antibody gene, with a myeloma cell that can grow endlessly. Alternatively, a
quick and powerful technique, phage display, allows the in vitro display of antigen binding
fragment (e.g., Fabs, scFvs) libraries on the surface of bacteriophage that encapsulate the
encoding DNA (217-221). The displayed antibody fragment libraries are screened against a
target molecule that is coupled to a solid support, enabling the isolation of phage particles
displaying antigen-specific antibodies.
Antibody library are constructed by either isolating the naturally occurring
immunoglobulin genes from B cells (222, 223) or using synthetic man-made approaches relying
on mutagenesis of complementarity determining regions (CDR) of the antibody (224). Semisynthetic approaches have also been used which combine both naturally occurring and synthetic

97
sequences (225). Man-made synthetic antibody libraries are constructed from structural and
functional knowledge of antibody-antigen interface (226, 227). Antigen recognition is primarily
mediated by complementarity determining regions (CDRs) that are located at the N-terminal end
of the antibody connected to the β-sheet framework (228, 229). DNA sequencing data has played
an important role in revealing the boundaries of amino acid diversity for CDRs and framework
regions in naturally occurring antibodies (230-232).
Camels and llamas produce a portion of their antibody repertoire devoid of light chains
(205). Consequently, the antigen-binding interface of VHH domains involves only three
hypervariable loops, CDR1-3. These heavy-chain-only antibodies possess the smallest natural
antigen-binding fragment (i.e., VHH). Genetic mechanisms determine the sequence variability
within the variable domains of naturally occurring antibodies (233, 234). A structure-based
database of variable domain CDR3 was previously studied for understanding roles of residues in
framework stabilization using naïve libraries and combinatorial alanine-scanning mutagenesis
(235, 236), which provided insight into CDR3 residues that should remain unchanged, and the
residues in CDR3 that are capable of substitutions, which opens opportunities for synthetic
libraries.
Here, we are interested in the long-term goal of developing synthetic single-domain
antibody libraries that can be used to develop novel antibodies in vitro. To enhance the use of the
VHH domain for synthetic libraries, we examined potential sequence diversity of CDR4, a nonhypervariable interface loop that is structurally well-placed to make contact with potential
antigens (237). The ability of CDR4 to possess wide sequence variation will be explored within
an anti-RNase A VHH antibody, a model VHH system that uses CDR1 and 3 for antigen
recognition (Figure 4.1). Synthetic CDR4 libraries were generated that sample all 20 amino acids,
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as well as vary loop length, ranging from four to seven residues. RNase A was then used as the
“bait” to select subpopulations of the library that possess functional CDR4 sequences. The
resulting amino acid and loop length diversity will be used to guide our next generation synthetic
VHH libraries.

Figure 4.1: Cartoon structure showing complex between anti-RNase
A VHH antibody and RNase A. The anti-RNase A VHH antibody
framework is yellow with CDR1 colored in red, CDR2 colored in
green, CDR3 colored in blue and CDR4 colored in cyan.

Structure of Bacteriophage
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Non-lytic bacteriophages fd and M13 are often used for phage display (43). These
phage particles possess a diameter of about 6.5 nm and length of 930 nm. The M13
bacteriophage genome is composed of 6400-nucleotide single stranded DNA, which includes
genes for nine coat proteins (Figure 5.1). Major coat protein pVIII has about 2700 copies. The cterminal of pVIII is composed of four basic amino acids, which are responsible for interaction
with phosphate groups of the virus ssDNA inside the phage. pIII and pVI (five copies each) are
found at the end of the bacteriophage and are involved in the phage detaching from the cell
membrane during the period of secretion from cell membrane (238). pVII and pIX (three to five
copies) are located at other end of the bacteriophage (239).
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Figure 4.2: Illustration showing life cycle of
filamentous phage f1 (M13/fd) (240)

Infection

Bacteriophage infect strains of E. coli that display F pili on their surface. The infection
process involves attachment of the N2 domain of pIII to the F pilus, as well as an interaction of
the N1 domain of pIII with the host protein To1A (Figure 4.2). These interactions result in
stretching the inner membrane allowing penetration into the host cell. The bacteriophage ssDNA
is released into the host cytoplasm by TolA proteins Q, R, A where it is converted to double
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stranded DNA (dsDNA), also known as a double-stranded replicative form (RF). RF acts as a
template to create more offspring RFs. This infection process occurs at temperature above 34°C
(normally at 37°C), where a thousand phages per cell are secreted within the first hour (240).

Figure 4.3: Schematic representation of bacteriophage infection
into E. coli (240)
For phage display purposes, foreign peptides/proteins can be displayed on a number of
surface of coat proteins, including pIII, pVII, pVIII, and pIX. The gene for the foreign
peptide/protein is introduced as a fusion protein at the N-terminal end of the coat protein (Cterminal end for pVI) (241, 242). The two coat proteins used most frequently are pIII (gene 3)
and pVIII (gene 8), each possesses different display strengths/weaknesses (55). The pIII and
pVIII coat proteins possess 406 and 50 amino acids, respectively, and participate in host cell
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infection. pIII can tolerate large insertions and is compatible with monovalent display (i.e.,
one foreign protein/phage particle), which is advantageous for higher affinity interactions. On the
other hand, pVIII, is frequently used for display of foreign proteins (especially peptides) that
possess weaker affinity, where the multivalent display of pVIII (2700 copies) serves to enhance
the apparent binding affinity.
Phage display libraries possess variant/diversity limits of approximately 1010.
Consequently, considerations have to be made while designing the libraries. For example, if full
diversity, i.e., all 20 amino acids, at a particular position is desired, only seven positions can fully
sample all 20 amino acids (207 = 1.28 × 109), as eight positions will be over the diversity (limit =
1 × 1010) of (208 = 2.56 × 1010).

Construction of Phage Display libraries

A phagemid is a plasmid that contains the foreign gene-coat protein fusion sequence that
will be packaged into phage particles. The vector also contains origins of replication for double
stranded and single stranded DNA synthesis, antibiotic resistance (ampicillin). In this study, the
foreign protein-coat protein fusion gene is under the control of the alkaline phosphatase promoter
(PphoA). The fusion protein also includes a stII periplasmic secretion signal, which directs the
foreign protein-coat protein fusion to the periplasmic space for phage particle assembly. On coinfection with helper phage M13K07, single stranded DNA replication is initiated, which allows
packaging of the protein of interest into a subset of new phage particles (typically 1-5%).
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Library Generation
The encapsulated ssDNA can be purified from the phage particle, which can then be used
for library construction using oligonucleotide-directed mutagenesis (140, 243, 244). The foreign
gene is present as a fusion with an M13 coat protein (e.g., pIII). Oligonucleotides containing
degenerate codons that encode many different protein sequences can be used with Kunkel
mutagenesis to introduce diverse DNA sequences that encode different protein sequences (245).
Uracil-containing single strand DNA is purified from E. coli strain CJ236 (dut-/ ung-). After
annealing to the dU-ssDNA, the oligonucleotide(s) containing the degenerative codons are
enzymatically extended and ligated to form covalently closed circular DNA. Typically these
approaches possess an approximate 75% success rate for a single oligonucleotide. The resulting
heteroduplex, covalently-closed, circular DNA was introduced into E. Coli for amplification and
phage propagation. The diversity of the library is limited by the efficiency of the DNA
incorporation into E. coli, which is accomplished through high voltage electroporation.
Application of electric field results in uptake of DNA into E. coli. E. coli SS320 was used for its
high electroporation efficiency. Multiple electroporations can be combined to produce diversity
greater then single electroporation (246).

Materials and Methods

M13K07 Amplification

M13KO7 helper phage is an M13 bacteriophage that carries the mutation Met40Ile in gII
and contains the origin of replication from P15A and the kanamycin resistance gene from Tn903
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(247). M13KO7 is able to replicate in the absence of phagemid DNA. In the presence of a
phagemid bearing a wild-type M13 or f1 origin, single-stranded phagemid is packaged
preferentially into phage particles, which are then secreted into the culture medium. A single
colony of E.coli XL-1 blue from a freshly made agar plate (2xYT/tet) is used to inoculate a 2 mL
(2xYT/tet) culture at 37°C with shaking (280 rpms). At midlog phase (OD600 = 0.55-0.70), which
typically takes 6-8 hrs, 500 µL of the midlog phase culture is used to inoculate 5 mL 2xYT/tet,
which incubates until midlog phage (typically 2-3 hrs). M13KO7 Helper phage (New England
Biolabs) is serial diluted with sterile PBS. Next, 10 µL of serial diluted helper phage is incubated
with 0.5 mL of midlog phage XL-1 blue cells for 30 min (37°C/235 rpm). Previously stored
2xYT Top Agar media was microwaved and then stored in 45 °C bath to prvent pre-mature
solidification. The helper phage stocks were mixed with 2 mL of top agar and plated on LB/Kan
plates and incubated for 24 hrs. at 37 °C.
A single M13KO7 plaque colony from the top agar plates was used to infect 1 mL midlog
XL-1 blue cells by incubating at 37°C for 30 min, followed by adding to 25 mL 2xYT/Kan (O/N
incubation at 37°C). Early next morning, 1/100 of the O/N subculture was added to 500 mL
2xYT/Kan in a 4L flask and incubated 16 hrs at 37°C with shaking (280 rpms). The culture was
then centrifuged for 10 min at 8,000 rpms at 4°C and the supernatant was transferred to a fresh
tube. Next, a 1/5 volume of the 20 % PEG 8000/2.5M NaCl solution was added, mixed, and
allowed to incubate on ice for 1 hr to precipitate the phage. The phage particles were isolated by
centrifugation for 20 min at 8000 rpms (4°C). The supernatant was carefully decanted and any
remaining supernatant was removed using a pipet without disturbing the phage pellet. The phage
pellet was resuspended in 1/20 volume (25 mL for 500 mL original culture) in PBS.
Resuspended phage pellet was spun down at 8,000 rpms to clarify the solution before measuring
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the phage concentration spectrophotometrically using a NanoDrop. An OD268 = 1.0
represents 5 × 1012 phage particles/mL. Phage particles may be stored; however, if higher
concentrations are needed, the phage may be subjected to another PEG/NaCl precipitation and
resuspended in a smaller volume of PBS. The final phage concentration (phage/mL) should not
exceed 1 × 1013 phage/mL. The helper phage stocks may be stored at 4° C for immediate use and
−80° C for long time storage.

CDR4 Library Generation

A phagemid vector contacting an anti-RNase A VHH gene upstream of M13 pIII was
kindly provided by S. Koide, University of Chicago (248). Using kunkel mutagenesis (249), stop
codons were introduced within the non-hypervariable loop CDR4 (Kabat Residues # 74-77) to
inhibit selection for wild type clones, using the following oligonucleotide:

CDR4: 5’-CGTTTCACCATCAGCCGTGACTAATAATAATAAACCGTATACCTGC
AGATGGAC-3’

Next, degenerative primers were designed to include all possible amino acids using the following
oligonucleotides:

CDR4-4: 5’ – CGTTTCACCATCAGCCGTGACNNSNNSNNSNNSACCGTATACC
TGCAGATGGAC-3’
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CDR4-5: 5’ – CGTTTCACCATCAGCCGTGACNNSNNSNNSNNSNNSACCGTAT
ACCTGCAGATGGAC-3’

CDR4-6: 5’ – CGTTTCACCATCAGCCGTGACNNSNNSNNSNNSNNSNNSACCG
TATACCTGCAGATGGAC-3’

CDR4-7: 5’ – CGTTTCACCATCAGCCGTGACNNSNNSNNSNNSNNSNNSNNSA
CCGTATACCTGCAGATGGAC-3’

Where N = A/T/G/C, S = C/G.
The “ NNS” degenerate codon encodes 32 possible codons. The library size of all four varying
length libraries are shown table 4-1. A large-scale Kunkel mutagenesis procedure was performed
using the previously designed stop-codon template phagemid.

Table 4.1: CDR4 library sizes for varying length
Library
size
324
1.04 × 106
325

3.35 × 107

326

1.07 × 109

327

3.43 × 1010

107

Lys76
Asn77
Gly75
Lys74

Figure 4.4: Cartoon structure of VHH showing four CDR4 residues
selected for library generation

Phage Propagation

Twenty micrograms of DNA for large-scale Kunkel mutagenesis was purified with a PCR
cleanup kit. The purified DNA was subdivided into three sterile microfuge tubes and three 350
µL aliquots of electrocompetent E. coli SS320 (thawed on ice) were slowly mixed with DNA
aliquots without introducing bubbles. Samples were transferred into 0.2 cm gap electroporation
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cuvettes while on ice. Electroporation was performed, using a BTX ECM-600
electroporation system, 2.5 kV field strength, 129 Ohms resistance and 50 uF capacitance.
Immediately after electroporation, 1.5 mL of SOC media was added to rescue the cells and then
transfer to a 250 mL-baffled flask. The cuvette was rinsed another time with SOC media to
remove remaining cells. The same procedure was repeated two times and 25 mL of SOC (final
volume) was added to the baffled flask and incubated for 20 min at 37°C with shaking at 235
rpm. A blank negative control electroporation, without any DNA, was performed for background
determination. Later 50 µL of sample was collected for serial dilutions to calculate the library
size prior to propagation The remaining amount of culture was transferred to a 4 L baffled flask
containing 500 mL 2xYT media, carb for phagemid vector resistance, helper phage M13K07 and
0.2 mM IPTG at 37°C overnight with shaking (235 rpm) for 16 hrs. Cultures are centrifuged
with 500 mL centrifuge tubes for 10 mins at 8000 rpm at 4°C. A 1/5 volume of 20 % PEG 8000
/2.5M NaCl solution was added to the supernatant to precipitate the phage. The sample was
incubated for 2 hrs on ice. The samples were centrifuged for 10 mins at 8,000 rpms at 4°C. The
supernatant was discarded, briefly respun, and remaining supernatant was removed using a
serological pipet. The pellet was suspended using 1/20 volume of PBS. The resuspended pellet
was centrifuged to clarify the solution. The final phage concentration was measured by titering.
All phage library stocks are stored in -80°C for long-term storage.

Phage Selection

Bovine serum albumin (BSA) was added to the phage library (0.5% W/V) to reduce
nonspecific clones/non-specific interactions. The phage library (with BSA) was then incubated
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with streptavidin coated magnetic beads to remove any nonspecific binding against beads or
streptavidin using a magnetic bead handler. The resulting supernatant was used for phage
selection against RNase A.
Phage selection involved incubation of 1012 phage particles with 20 µM biotinylated
RNase A in PBS buffer (20 mM sodium phosphate, 150 mM sodium chloride, pH 7.4). Phage
particles displaying VHH variants that recognized RNase A were captured using magnetic
streptavidin coated beads with the aid of a King Fisher magnetic bead handler. Six wash steps
were performed with PBS/Tween-20 buffer, pH 7.4 to remove non-specific binding variants.
Phage particles bound to the biotinylated RNase A target, which were captured by the
streptavidin-coated magnetic beads, were eluted using 0.1 mM DTT (dithiothreitol), which
reduces the disulfide bond within the biotin linker. Eluted phage particlers were amplified by
incubating with 2 mL midlog phase XL-1 blue cells for 20 min at 37°C, transferred to a 30 mL
2xYT/Amp/M13KO7/Tet culture and incubated at 37°C (235 rpm) for 16 hrs. Cultures were
centrifuged for 10 min at 8,000 rpm at 4°C. Next 1/5 volume (6 mL) of the PEG/NaCl solution
was added to precipitate the phage. The solution was incubated for 2 hrs on ice. The samples
were then centrifuged for 10 min at 8,000 rpm at 4°C. The supernatant was discarded after brief
spin and the remaining supernatant was removed using a serological pipet. The pellet was
suspended using the 1/20 volume of PBS (1.5 mL). The resuspended pellet was centrifuged at
14,000 rpm for 5 min to remove any insoluble pellet. The amplified phage was used for further
rounds using selection procedure as above.
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Figure 4.5: Phage display selection cycle. Biotinylated anti-RNase
A VHH is incubated with phage library and selected clones are
amplified for further rounds of selection.

Single-Point Phage ELISA
ELISA is a color based calorimetric assay frequently used to investigate protein-protein
binding interactions. Using ELISA, multiple VHH clones, which are displayed on phage
particles, can be screened for target binding in a single experiment. The phage selection process
should yield a phage pool enriched with antigen binding clones; however, the phage pool may
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also include phage particles selected for alternate reasons (such as non-specific binding).
Single point phage ELISA was used as a quick method to establish single clones that bind the
target antigen.
Using 96-well deep well plates, 300 µL aliquots of 2xYT/carb/M13K07/0.2mM IPTG
media were inoculated with a single colony of XL-1 cells containing a phagemid clone and
allowed to grow overnight at 37 °C with shaking (235 rpm). Maxisorb plates are coated with 100
µl of 20 µg/mL target made up of coating buffer (50 mM Sodium Bicarbonate at pH 9.4) and are
incubated overnight at 4 °C. Controls wells, coated with coating buffer containing BSA 0.5%
(w/v), were also included. The next morning, the coating buffer was removed and the maxisorb
plates were blocked with 200 µL of blocking buffer (0.5% BSA, PBS, pH 7.4) for 1 hr. The
overnight 300 µL cultures were centrifuged at 3,500 rpm for 10 min before transferring the
phage-containing supernatant to a fresh plate containing three-fold volumes of PBS buffer.
Diluted phage supernatant was transferred onto the maxisorb plate and incubated for 1 hr under
slow shaking. Unbound phage was removed by washing the plate six times with PBS-T (sodium
phosphate buffer containing 0.5% Tween 20). Next 100 µL of horseradish peroxidase/anti-M13
antibody conjugate (diluted 1:1250 in PBS-T buffer) was added to each well. After 30 min of
incubation with gentle shaking, the antibody solution was removed and the plate was wash six
times with PBS-T, followed by two washes with PBS. Finally, 100 µL of TMB substrate was
added to each well. The color was allowed to develop for 5-10 min before stopping the reaction
by the addition of 100 µL/1M sulfuric acid. Absorbance was measured at 450 nm on microtiter
plate reader.
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Secondary
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Antibody
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Figure 4.6: Schematic picture of Enzyme Linked
Immunosorbent Assay (ELISA).
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Results and Disscusions

Selection of VHH CDR4 Length that Complement the VHH Domain Fold

VHH interacts with RNase A using CDR1 and CDR3. The non-hypervariable CDR4
loop does not interact with RNase A, although it is structurally well placed to make contacts with
potential targets (250-252). Here, the anti-RNase VHH scaffold will allow CDR4 loop diversity
to be explored as it is not directly involved in the interaction with RNase A. Those CDR4
variants that correctly fold (i.e., remain functional) may be selected based on their ability to
recognize the RNase A target. The CDR4 loop diversity (both in terms of residues and loop
length) was explored to investigate the structural boundaries within CDR4 that will facilitate
future design efforts of synthetic VHH libraries.
Kabat residues 74-77 (figure 4.4) were selected for randomization by inserting “NNS”
degenerative codons with varying length (n=4, 5, 6, and 7). These degenerative NNS codons
contain 32 unique codons for each position, which ensures all 20 naturally-occuring amino acids
may be sampled. The four libraries with varying loop lengths were mixed together with equal
number (2.5 × 1011 phage/mL) and were subjected to three rounds of binding and selection to
enrich for library with functional (i.e., capable of binding RNase A), correctly folded VHH
clones. Twelve clones from the 3rd round selection were sent for sequencing to guage the
selection progress.
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Table 4.2: Enrichments results for three rounds of selection for 4, 5,
6, and 7 length libraries against RNase A; N/A= Not Measured
Experiment
Control
Enrichment
Round #1

N/A

N/A

N/A

Round #2

1.0 × 105

9.0 × 103

11.1

Round #3

4.0 × 104

2.0 × 104

2.0

Table 4.3: Amino acid distribution and CDR4 length distribution of
library NNS following the three round selection for RNase A
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N

K

N
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K

D

G

R

I
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-

K

R

R

M

G

-

-

Y

S

L

K

P

P

R

In the small subset of samples we sequenced there was no clones present with a CDR4
loop length of six, while three, four and one clone(s) were observed containing loop lengths of
four, five and seven, respectively. CDR4-5 (the 5 length loop) library was used for further
selection as it had highest number of clones from the mixed library selection. Remaining clones
consisted of stop codons.
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Selection of VHH CDR4-5 Length
The CDR4-5 phage library was cycled through three rounds of binding and selection to
enrich the library with members that were capable of binding RNase A, and thus likely of proper
VHH fold. No significant enrichments was observed (table 4-4).

Table 4-4: Enrichments results for three rounds of selection for
CDR4-5 phage library against RNase A
Experiment
Control

Enrichment

Round #1

6.0 × 106

1.2 × 106

None

Round #2

1.4 × 106

8.0 × 105

None

Round #3

3.0 × 106

4.0 × 106

0.75

Troubleshooting for Non-Specific Binding
A large number of non-specific clones were observed through the selection process.
To remove nonspecific binding phage library members, prior to library selection, the phage
library was incubated in an eppindorf tube for 1 hr at room temperature with slow shaking to
remove phage sticking against the eppindorf tube. Later, the supernatant was incubated with
streptavidin coated magnetic beads for 1 hr at room temperature with slow shaking. A magnet
stand was used to remove non-specific phage, which were bound to the streptavidin coated
magnetic beads. Remaining phage were then used for selection against target RNase A. While
selecting, excess washing steps were included (12 washes), to minimize non-specific binding,
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before eluting with DTT. These additional steps resulted in a significant increase in the
observed enrichments (table 4-5).

Table 4-5: Enrichments results for three rounds of selection CDR45 phage library against RNase A after troubleshooting
Experiment
Control
Enrichment
Round #1

1.0 × 107

5.0 × 105

50

Round #2

4.0 × 105

2.0 × 104

20

Round #3

6.0 × 106

8.0 × 104

75

The observed enrichment may be due to removing non-specific binders from the
inclusion of additional wash steps and incubation of phage with streptavidin coated magnetic
beads prior to selection to remove any nonspecific clones against beads. After the 3rd round of
selection, 11 single phage clones were amplified individually and the diluted supernatant was
used for a functional phage ELISA (Figure 4-7).
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Figure 4.7: Bar graph showing the ELISA data for select clones.
The difference in absorbance signal between clones boud with
(Blue) and without target (Violet). ID 12 was the wild type
phage (positive control).

After ELISA testing, 11 of the clones tested were sent for DNA sequencing. Of those
clones, the five clones that showed functional binding based on the ELISA assay, also showed
appropriate sequences (e.g., no stop codons/parent template). The remaining six sequenced
clones possessed wild-type template, containing stop codons. The presence of the wild-type
template clones suggests nonspecific binding was still present.
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Table 4-6: Amino acid sequences of CDR4-5 VHH variants which
showed positive results for functional assays
CLONE ID
CDR4
Wt

I

R

S

D

-

T

V Y

4

I

R

S

D V N Y N

I

7

I

R

S

D G K G

S

8

I

R

S

D G G G
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I

R

S

D
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I

R

S

D R
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S
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-

L

Q

F

T

V Y

L

Q

N

T

V Y

L

Q

L

R

T

V Y

L

Q

K G V

I

T

V Y Q Q

C
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T

V Y

F
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L

Q

To obtain a broad view of the selected population, we sequenced one hundred of the
selected clones from round 3. As described below in Table 4.7, the broad sampling of the
selected clones enabled us to identify general trends in sequence conservation as revealed by
aggregate analysis of the clones.
Of the 100 clones sequenced after three rounds of binding selection against RNase A, 58
unique sequences were identified that constituted a non-redundant data set. The remaining 42
clones included stop codons, although the reasons behind their presence, even after the additional
wash step, is unclear. The 58 sequences were aligned, and the occurrence of each amino acid at
each of the 5 positions within the loop was tabulated. The totals were then normalized by
dividing by the number of times each amino acid was encoded by the redundant NNS codon. For
example, the NNS codon contains three unique codons for Arg, Ser, and Leu; therefore, these
three amino acid totals at each position was divided by 3 to correct for the bias. The resulting
normalized data for amino acids at different positions is shown in figure 4.4.
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Position 74 mostly consists of large hydrophobic amino acid tryptophan and charged
residues lysine/aspartic acid, surprisingly no polar residues are observed at position 74. Position
75 mostly consists of glycine and polar asparagine. Position 76 favored the positively charged
amino acid lysine. In fact, lysine was the original parent amino acid in position 76 of the wildtype anti-RNase A VHH, suggesting its conservation may be critical to the VHH fold. Position
77 consists of bulky aromatic hydrophobic tryptophan and glycine residues. The reasons behind
the bulky aromatic hydrophobic tryptophan residue are not clear. Glycine occurrence was
significant in position 75,76,77 near the central position of the loop, which might be due to the
fact that glycine facilitates some flexibility for turn formation. Position 78 mostly consists of
polar residues threonine and asparagine. This knowledge can be further used to design next
generation synthetic libraries with more controlled insertion of degenerate codons.

Table 4.7: Percentage occurrence of each amino acid type at each position in CDR4. calculated
after nomalization of codon bias. Non polar amino acids are coloured in yellow, polar in light
green and charged in blue. The most abundant residues type at each position is colored in dark
green.
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Conclusions
To enhance the use of the VHH domain for synthetic libraries, we explored potential
sequence diversity of CDR4, an interface loop that is not a natural hypervariable loop, but is
structurally well placed to make productive contact with potential antigens. The anti-RNase A
VHH was used as a model system, which acts as a VHH selection agent. Stop codons were
inserted into CDR4 so that wild-type anti-RNase A VHH was not selected. Degenerate codons
inserting all 20 amino acids, with different loop lengths ranging from four to seven were inserted
to explore CDR4’s potential amino acid and loop length diversity. Initial studies with loop length
of five amino acids showed positive enrichment and the binding of clones against target RNase
A was confirmed using a single point phage ELISA. The resulting amino acid and loop length
diversity will be used to build our next generation synthetic VHH libraries.

Chapter 5

CONCLUSIONS
The work discussed in this dissertation uses an anti-RNase A VHH single domain
antibody as a model system for exploring new protein engineering methods to enhance protein
interactions. Chapter 2 aimed to better understand the thermodynamic origins of an affinitymatured antibody, VHH-Mat, through systematic site-directed mutant analysis. Chapter 3
discussed the generation of an anti-RNase A VHH bivalent complex, which possessed an
enhanced observed binding affinity, as compared to the original monovalent VHH. Chapter 4
used synthetic library techniques to investigate potential sequence and loop length diversity of
non-hypervariable loop CDR4.
Antibody-antigen interactions play an important role in the immune response (253) and a
variety of life science applications, consequently, a better understanding of the binding
energetics that drive these interactions is of interest. Chapter 2 examined the thermodynamic
origins of an in vitro affinity matured anti-RNase A VHH Antibody (VHH-mat), as compared to
the original in vivo generated parent antibody (VHH-Wt). Single, double, triple, CDR1-only,
CDR3-only variants were all generated by exchanging wild-type residues with the corresponding
VHH-mat residues. The binding thermodynamics of the different VHH variants, as determined
using ITC, suggested intramolecular interactions played a significant role in the resulting
enhanced binding affinity. Such interactions can stem from hydrophobic, electrostatic and van
der Waals interactions between two or more residues (254-256). The cooperative interactions,
which included both positive & negative contributions, were observed between CDR3 loop
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residues Y101D/T107R & E102A/R104V, respectively. Notably, the only intramolecular
interactions that were observed were intra-loop (CDR3), with no intramolecular contributions
originating between CDR1 & 3. This finding appears to agree with the fact that initial selection
explored full amino acid diversity within CDR1 and CDR3 individually, before combining the
selected CDR1 and CDR3 sub-populations for final selection (139). These results suggest that
future library-based strategies to enhance protein affinity may benefit from libraries that
introduce residues that have the potential to make favorable intramolecular interactions. These
libraries must take into consideration not only the potential for intra-molecular interactions based
on the properties of the sidechain, but also the localized environment, as intra-molecular
interactions between two or more residues will most likely require close proximity.
Antibody fragments (e.g., VHH, Fabs) with weak antigen binding affinity typically
require affinity maturation or construction of multivalent systems that introduce high functional
affinity to improve diagnostic and therapeutic behaviors of the antibody. Site-specific in vivo
biotinylation was described by Schatz in 1993, as a method to engineer phycocerythrinstreptavidin producing a multivalent interaction (257). Compared to a monovalent system,
multimerization increases the availability of multivalent binding sites on an antigen converting
sdAbs into multivalent system may, in particular increase their functional affinity. Using a
similar strategy, a single-domain antibody containing a C-terminal Avitag peptide was
biotinylated and allowed to form a bivalent complex using the protein rhizavidin. The formation
of the bivalent system was confirmed by SDS-PAGE and size exclusion chromatography.
Surface plasmon resonance was used to evaluate the resulting effect on observed affinity, which
indicated the bivalent system possessed a 100-fold higher apparent binding relative to the
monovalent sdAb. While there was no significant difference in the observed on-rates, the
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increase in apparent binding affinity was attributed to a significant increase in the off-rate of
bivalent system compared to the original monovalent sdAb. The ease of expression of rhizavidin
and the ability to combine components in stoichiometric ratios to rapidly produce a bivalent
complex makes this approach appealing. Furthermore, this system represents a generic and
practical in vitro approach to generate high functional affinity of bivalent systems, which should
be easily adapted to other antibody fragments, such as scFv and Fab. The resulting bivalent
complexes can be used for a range of diagnostic and immobilization methods that may help
improve the limit of detection, as well as affinity reagent applications where long-off rates are
required.
Antibody libraries are constructed either by isolating the naturally occurring
immunoglobulin gene from B cells or using synthetic man-made libraries. Synthetic antibody
libraries are constructed from structural and functional knowledge of antibody- antigen interfaces.
In particular, antigen recognition is mediated by complementarity determining regions (CDRs).
The antigen-binding interface of the VHH domain found in heavy-chain-only antibody produced
by the camelid family (e.g., camels and llamas) possess the smallest natural antigen-binding
fragment. A library-derived database of the non-hypervariable CDR4 loop from VHH was
examined to explore its potential use in synthetic libraries. Initially, CDR4 loop lengths of 4, 5, 6
and 7 were generated to explore the role of expanded length on proper VHH folding. Based on a
high population of the resulting library containing CDR4 loops with five residues, the CDR4-5
residue library was individually subjected to functional selection and sequencing (one hundred
clones). Interestingly, parent amino acid residues, from wild type anti-RNase A VHH, at position
74, 75, 76 appeared more than expected, relative to random occurrence, which suggests their
presence may be important to the VHH fold stability and/or solubility. Although a higher than
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expected occurrence of glycine as residue positions 75, 76, and 77 suggest conformational
many of the residues that were allowed may be conformationally constraining. As the CDR4-5 (5
length loop) library was originally selected from a larger population of samples that contained an
expanded range of loop lengths, a better understanding of the role of loop lengths and residue
diversity can only come from the study of these additional loop length possibilities (e.g., 6,7,8
residues). Using the knowledge of residue occurrence at each position we can develop future
antibody libraries that possess unique properties as compared to their naturally-derived
counterpart. It is possible that such antibody libraries may be particularly useful for affinity
maturation, as the CDR4 loop is structurally well positioned to make potential contacts with
target antigens. Finally, the potential to elucidate biophysical antibody constraints through in
vitro screening will enhance our knowledge of antibody structure and function that may allow
the development of synthetic antibodies that exceed the biophysical properties of naturallyderived antibodies.
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